Improved FOLR1 protease activatable t cell bispecific antibodies

By designing protease-activated T cells to activate bispecific molecules, using peptide linker and protease recognition sequence XQARK for reversible masking, the problem of difficulty in distinguishing bispecific molecules in target cells and normal cells is solved, and the problem of achieving the problem of Efficient activation and specific destruction.

CN118946586APending Publication Date: 2024-11-12F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030360.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-27
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing bispecific molecules are difficult to distinguish between target cells and normal cells, resulting in potential toxicity and unspecific activation, making it difficult to achieve a safe and efficient distinction between tumor cells and healthy cells.

Method used

A protease-activated T cell activation bispecific molecule was designed, covalently linked to the T cell activation bispecific molecule through a peptide linker, including the CD3 binding part and the target cell antigen binding part, and reversible masking is used to use the protease recognition sequence XQARK. , ensure that the tumor microenvironment remains low and is effectively activated at the site of action.

Benefits of technology

It improves the safety and specificity of the molecule, reduces toxicity, ensures effective activation at the target cells and destruction of tumor cells, while avoiding unnecessary damage to healthy cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005059517030000841
    Figure BDA0005059517030000841
  • Figure BDA0005059517030000851
    Figure BDA0005059517030000851
  • Figure BDA0005059517030000861
    Figure BDA0005059517030000861
Patent Text Reader

Abstract

The present invention generally relates to improved protease activatable antigen binding molecules comprising an anti-idiotype binding moiety that reversibly masks the CD3 antigen binding moiety of the molecule. Furthermore, the present invention relates to novel protease cleavable peptide linkers and their use in such protease activatable antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such protease-activated T cell binding molecules, as well as vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activated T cell binding molecules of the invention, and to methods of using these molecules, for example in the treatment of disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to improved protease-activatable antigen binding molecules comprising an anti-idiotypic binding portion that reversibly masks the CD3 antigen binding portion of the molecule. In addition, the present invention relates to novel protease-cleavable peptide linkers and their use in such protease-activatable antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The present invention further relates to methods for producing protease-activated T cell binding molecules of the present invention, and to methods of using these molecules, for example, in the treatment of diseases. Background Art

[0002] In various clinical settings, it is often necessary to selectively destroy single target cells or specific target cell types. For example, a major goal of cancer therapy is to specifically destroy tumor cells while leaving healthy cells and tissues intact.

[0003] An attractive approach to achieve this goal is to induce an immune response against the tumor so that immune effector cells, such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs), attack and destroy tumor cells. In this regard, bispecific antibodies designed to bind to surface antigens on target cells with one "arm" and to the activated non-variant component of the T cell receptor (TCR) complex have attracted attention in recent years. The simultaneous binding of this antibody to its two targets will force a temporary interaction between the target cell and the T cell, thereby activating any cytotoxic T cells and subsequently lysing the target cell. Therefore, the immune response is redirected to the target cell and is independent of the peptide antigen presentation of the target cell or the specificity of the T cell, while being related to the activation of the CTL restricted by the normal MHC.

[0004] In this context, it is crucial that CTLs are activated only when in close proximity to target cells, i.e., mimicking an immune synapse. In particular, the desired T cell activating bispecific molecules do not require lymphocyte pretreatment or co-stimulation to elicit efficient lysis of target cells. Several bispecific antibody formats have been developed and investigated for their suitability for T cell-mediated immunotherapy. Such bispecific antibody formats include BiTE (bispecific T cell engager) molecules (Nagorsen and Exp Cell Res 317, 1255-1260 (2011)), diabodies (Holliger et al., Prot Eng 9, 299-305 (1996)) and their derivatives such as tandem diabodies (Kipriyanov et al., J Mol Biol 293, 41-66 (1999)), DART (dual affinity retargeting) molecules (Moore et al., Blood 117, 4542-51 (2011)) and triomabs (Seimetz et al., Cancer Treat Rev 36, 458-467 (2010)).

[0005] The task of generating bispecific molecules suitable for treatment provides several technical challenges related to efficacy, toxicity, applicability and manufacturability that must be met. In the case of bispecific molecules targeting antigens expressed in tumor cells but also expressed in normal tissues, on-target / off-tumor toxicity may occur. There is therefore a need for effective T cell activating bispecific molecules that initiate complete T cell activation in the presence of target cells but not in the presence of normal cells or tissues. Summary of the invention

[0006] The present invention provides improved T cell activation bispecific molecules. In particular, the present invention provides protease-activatable T cell activation bispecific molecules that have reduced or non-existent activity before reaching the site of action, such as, for example, the tumor microenvironment. This allows for improved safety, such as lower toxicity and effective activation of molecules at the site of action.

[0007] In one embodiment, a protease-activatable T cell activating bispecific molecule is provided, comprising

[0008] (a) a first antigen binding portion capable of binding to CD3;

[0009] (b) a second antigen binding moiety capable of binding to a target cell antigen; and

[0010] (c) a masking moiety covalently linked to the T cell activating bispecific molecule via a peptide linker, wherein the masking moiety is capable of binding to the idiotype of the first antigen binding moiety or the second antigen binding moiety, thereby reversibly concealing the first antigen binding moiety or the second antigen binding moiety,

[0011] The linker comprises a protease recognition sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

[0012] In one embodiment, the masking moiety is covalently attached to the first antigen binding moiety and reversibly conceals the first antigen binding moiety.

[0013] In one embodiment, the masking moiety is covalently linked to the heavy chain variable region of the first antigen binding moiety.

[0014] In one embodiment, the masking moiety is a scFv.

[0015] In one embodiment, (i) the second antigen binding moiety is a conventional Fab, or (ii) the second antigen binding moiety is a crossover Fab molecule, wherein the Fab light chain is exchanged with the variable region or constant region of the Fab heavy chain.

[0016] In one embodiment, the first antigen binding moiety is a conventional Fab molecule.

[0017] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a third antigen binding moiety which is a Fab molecule capable of binding to a target cell antigen.

[0018] In one embodiment, the third antigen binding moiety is identical to the second antigen binding moiety.

[0019] In one embodiment, the target cell antigen is FolR1.

[0020] In one embodiment, the first antigen binding moiety and the second antigen binding moiety are fused to each other, optionally via a peptide linker.

[0021] In one embodiment, the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety.

[0022] In one embodiment, the protease-activatable T cell activating bispecific molecule additionally comprises an Fc domain composed of a first subunit and a second subunit capable of stably associating.

[0023] In one embodiment, the Fc domain is an IgG, specifically an IgG1 or IgG4 Fc domain.

[0024] In one embodiment, the Fc domain exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain.

[0025] In one embodiment, the antigen binding portion capable of binding to CD3 comprises a heavy chain variable (VH) region

[0026] (a) heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SYAMN (SEQ ID NO: 1);

[0027] (b) HCDR2 amino acid sequence of RIRSKYNNYATYYADSVKG (SEQ ID NO: 2);

[0028] (c) the HCDR3 amino acid sequence of ASNFPASYVSYFAY (SEQ ID NO: 3);

[0029] and a light chain variable (VL) region comprising:

[0030] (d) the light chain complementarity determining region (LCDR) 1 amino acid sequence of GSSTGAVTTSNYAN (SEQ ID NO: 7);

[0031] (e) LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and

[0032] (f) a LCDR3 amino acid sequence selected from ALWYSNLWV (SEQ ID NO: 9).

[0033] In one embodiment, the antigen binding portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10.

[0034] In one embodiment, the antigen binding portion capable of binding to CD3 comprises: a heavy chain variable (VH) region comprising

[0035] (a) heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SYAMN (SEQ ID NO: 1);

[0036] (b) HCDR2 amino acid sequence of RIRSKYNNYATYYADSVKG (SEQ ID NO: 2);

[0037] (c) HCDR3 amino acid sequence of HTTFPSSYVSYYGY (SEQ ID NO: 4);

[0038] and a light chain variable (VL) region comprising:

[0039] (d) the light chain complementarity determining region (LCDR) 1 amino acid sequence of GSSTGAVTTSNYAN (SEQ ID NO: 7);

[0040] (e) LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and

[0041] (f) a LCDR3 amino acid sequence selected from ALWYSNLWV (SEQ ID NO: 9).

[0042] In one embodiment, the antigen binding portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 6; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0043] In one embodiment, the masking portion comprises: a VH region comprising:

[0044] (a) the HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15),

[0045] (b) a HCDR2 amino acid sequence selected from the group consisting of WINTETGEPRYTDDFKG (SEQ ID NO: 16), WINTETGEPRYTDDFTG (SEQ ID NO: 17) and WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0046] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0047] and a VL region comprising:

[0048] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25) or KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0049] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0050] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28) or QQSREFPYT (SEQ ID NO: 29).

[0051] In one embodiment, the masking portion comprises: a VH region comprising:

[0052] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0053] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0055] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0056] and a VL region comprising:

[0057] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0058] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0059] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0060] In one embodiment, the masking portion comprises: a VH region comprising:

[0061] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0062] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0064] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0065] and a VL region comprising:

[0066] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0067] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0068] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0069] In one embodiment, the masking portion comprises: a VH region comprising:

[0070] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0071] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFTG (SEQ ID NO: 17);

[0073] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0074] and a VL region comprising:

[0075] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0076] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0077] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0078] In one embodiment, the masking portion comprises: a VH region comprising:

[0079] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0080] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0082] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0083] and a VL region comprising:

[0084] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0085] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0086] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0087] In one embodiment, the masking portion comprises: a VH region comprising:

[0088] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0089] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0091] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0092] and a VL region comprising:

[0093] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0094] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0095] (f) LCDR3 amino acid sequence of QQSREFPYT (SEQ ID NO: 29).

[0096] In one embodiment, the second antigen binding moiety is capable of binding to FolR1 and comprises: a VH region comprising:

[0097] a) HCDR1 amino acid sequence of NAWMS (SEQ ID NO: 11);

[0098] b) the HCDR2 amino acid sequence of RIKSKTDGGTTDYAAPVKG (SEQ ID NO: 12); and

[0099] c) HCDR3 amino acid sequence of PWEWSWYDY (SEQ ID NO: 13);

[0100] and a VL region comprising:

[0101] d) LCDR1 of GSSTGAVTTSNYAN (SEQ ID NO:7);

[0102] e) the LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and

[0103] f) LCDR3 amino acid sequence of ALWYSNLWV (SEQ ID NO: 9).

[0104] In one embodiment, the antigen binding portion capable of binding to FolR1 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0105] In one embodiment, the protease-cleavable linker comprises the protease recognition sequence PQARK (SEQ ID NO: 41).

[0106] In one embodiment, an idiotype-specific polypeptide is provided for reversibly concealing an anti-CD3 antigen binding site of a molecule, wherein the idiotype-specific polypeptide is covalently linked to the molecule via a peptide linker, wherein the linker comprises a protease recognition sequence (XQARK SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

[0107] In one embodiment, the idiotype-specific polypeptide is an anti-idiotype scFv.

[0108] In one embodiment, the molecule is a T cell activating bispecific molecule.

[0109] In one embodiment, the linker comprises the protease recognition sequence PQARK (SEQ ID NO: 41).

[0110] In one embodiment, a pharmaceutical composition is provided, comprising a protease-activatable T cell activating bispecific molecule as described herein and a pharmaceutically acceptable carrier.

[0111] In one embodiment, a pharmaceutical composition is provided, comprising an idiotype-specific polypeptide as described herein and a pharmaceutically acceptable carrier.

[0112] In one embodiment, an isolated polynucleotide encoding a protease-activatable T cell activating bispecific antigen binding molecule as described herein is provided.

[0113] In one embodiment, an isolated polynucleotide encoding an idiotype-specific polypeptide as described herein is provided.

[0114] In one embodiment, a vector is provided, in particular an expression vector, comprising a polynucleotide as described herein.

[0115] In one embodiment, a host cell is provided, comprising a vector as described herein.

[0116] In one embodiment, a method for producing a protease-activatable T cell activating bispecific molecule is provided, comprising the steps of: a) culturing a host cell as described herein under conditions suitable for expressing the protease-activatable T cell activating bispecific molecule, and b) recovering the protease-activatable T cell activating bispecific molecule.

[0117] In one embodiment, a protease-activatable T cell activating bispecific molecule as described herein is provided for use as a medicament.

[0118] In one embodiment, the medicament is used to treat cancer or delay its progression, treat immune-related diseases or delay its progression, or enhance or stimulate the immune response or function of an individual.

[0119] In one embodiment, provided is a use of a protease-activatable T cell activating bispecific molecule as described herein for the manufacture of a medicament for treating a disease.

[0120] In one embodiment, a use of a protease-activatable T cell activating bispecific molecule as described herein is provided, wherein the disease is cancer.

[0121] In one embodiment, a method of treating a disease in an individual is provided, comprising administering to the individual a therapeutically effective amount of a composition comprising a protease-activatable T cell activating bispecific molecule as described herein.

[0122] In one embodiment, the method is used to treat or delay the progression of cancer.

[0123] Other technical features will be apparent to those skilled in the art from the following drawings, descriptions and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0124] Figure 1 . Schematic diagram depicting exemplary protease-activatable FolR1 TCB molecules (SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:53).

[0125] Figure 2 .Depicts the study design for single-dose PK and stability studies. Female NSG mice were injected intravenously with protease-activatable FolR1 TCB molecules containing HQARK or PQARK (Groups A and B) linkers and compared with a typical FolR1 TCB molecule (Group C). Mice were bled at 24 hours, 7 days, and 10 days after injection. Serum was prepared and analyzed by ELISA for total and active forms of FolR1 TCB molecules.

[0126] Figure 3. Quantification of active pro-TCB in the serum of non-tumor bearing mice is depicted. Measurement of active and total TCB concentrations in serum over time after a single iv injection of protease-activatable FolR1 TCB or canonical FolR1 TCB was performed by ELISA. Active and total TCB were quantified by ELISA using anti-PG antibody (protease-activatable FolR1 TCB) and anti-idiotypic anti-CD3 antibody (active FolR1 TCB). Active TCB is shown as a percentage of total TCB. Dose correction was not required because equimolar doses of protease-activatable FolR1 TCB and canonical FolR1 TCB were used in the respective studies.

[0127] Figure 4 .Describes the study design of the in vivo efficacy study. Female NSG mice were injected subcutaneously with human breast cancer PDX (BC004) and received the first treatment when the tumor reached approximately 200mm3 in size (day 28). Mice were treated intravenously once a week with protease-activatable FolR1 TCBs containing cleavage sites for PMAKK or PQARK (groups D and E) molecules, or typical FolR1 TCB molecules (group B) and masked FolR1 TCBs containing non-cleavable linkers (group C). One group received only histidine buffer and served as a control group (group A; vehicle). Tumor growth was measured by caliper gauges, and the study was terminated on day 58, and tumors were harvested and weighed.

[0128] Figure 5. Depicts tumor growth inhibition and tumor weight at study termination. (A) Depicts mean + / - SEM of tumor volume over time for all treatment groups. Protease-activatable FolR1 TCB molecules containing a PQARK cleavage site resulted in tumor growth inhibition comparable to that seen for the typical FolR1 TCB. Masked FolR1 TCBs containing a non-cleavable linker and molecules containing a PMAKK cleavage site did not result in tumor growth inhibition. (B to F) Shows individual tumor growth kinetics for a single mouse in vehicle (B), typical FolR1 TCB (C), protease-activatable FolR1 TCB containing a PMAKK site (D), masked FolR1 TCB containing a non-cleavable linker (E), and protease-activatable FolR1 TCB containing a PQARK cleavage site (F). (G) Tumor weights for all treatment groups at the end of the study.

[0129] Figure 6 .Depicts Jurka NFAT activation induced by protease-activatable FolR1 TCB molecules containing CD3 binder clone 22. DETAILED DESCRIPTION

[0130] definition

[0131] Unless otherwise defined below, the terms used herein are generally as used in the art.

[0132] "Acceptor human framework" for the purposes of this paper is such a framework, which comprises the amino acid sequence of the light chain variable domain (VL) framework or the heavy chain variable domain (VH) framework derived from the human immunoglobulin framework or people's shared framework as defined below. The acceptor human framework "derived from" the human immunoglobulin framework or people's shared framework may comprise the amino acid sequence identical to the human immunoglobulin framework or people's shared framework, or it may comprise amino acid sequence changes. In some aspects, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less or 2 or less. In some aspects, the VL acceptor human framework is identical to the VL human immunoglobulin framework sequence or people's shared framework sequence in sequence.

[0133] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D ) represents. Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described below.

[0134] An "affinity matured" antibody is one with one or more alterations in one or more complementarity determining regions (CDRs) which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess such alterations.

[0135] The term "antibody" herein is used in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0136] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv and scFab); single domain antibodies (dAb); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23:1126-1136 (2005).

[0137] Screening for antibody binding can be performed using methods routine in the art, such as, but not limited to, alanine scanning, peptide blotting (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496) and cross-blocking (see "Antibodies", Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY).

[0138] Antibody profiling based on antigen structure (ASAP), also known as modification-assisted profiling (MAP), allows a large number of monoclonal antibodies that specifically bind to an antigen to be binned according to the profiling of each antibody binding to a large number of chemically or enzymatically modified antigen surfaces (see, e.g., US 2004 / 0101920). The antibodies in each group bind to the same epitope, which can be a unique epitope that is significantly different from or partially overlaps with the epitope represented by another group.

[0139] In some aspects, two antibodies are considered to bind to the same or overlapping epitope if one antibody inhibits the binding of the other antibody by at least 50%, at least 75%, at least 90%, or even 99% or more by 1, 5, 10, 20, or 100-fold excess as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50 (1990) 1495-1502).

[0140] In some aspects, two antibodies are considered to bind to the same epitope if substantially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other antibody. Two antibodies are considered to have an "overlapping epitope" if only a subset of amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody.

[0141] Terminal epitope part]]

[0142] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0143] The "class" of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these antibodies can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In some aspects, the antibody is an IgG1 isotype. In some aspects, the antibody is an IgG1 isotype with P329G, L234A, and L235A mutations to reduce the effector function of the Fc region. In other aspects, the antibody is an IgG2 isotype. In some aspects, the antibody is an IgG4 isotype with an S228P mutation in the hinge region to improve the stability of the IgG4 antibody. The heavy chain constant domains corresponding to different classes of immunoglobulins are referred to as a, d, e, g, and m, respectively. The light chain of an antibody can be classified into one of two types based on the amino acid sequence of its constant domain, which are called kappa (κ) and lambda (λ).

[0144] As used in the present application, the term "human-derived constant region" or "human constant region" refers to the constant heavy chain region and / or constant light chain kappa or lambda region of a human antibody of subclass IgG1, IgG2, IgG3 or IgG4. Such constant regions are well known in the prior art and are described, for example, by Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, for example, Johnson, G., and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, EA, et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, the numbering of amino acid residues in the constant region is according to the EU numbering system (also known as Kabat's EU index) as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

[0145] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

[0146] An "effective amount" of a pharmaceutical agent (eg, a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0147] The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, which comprises at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the antibody produced by the host cell can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, the antibody produced by the host cell by expressing a specific nucleic acid molecule encoding a full-length heavy chain can include a full-length heavy chain, or the antibody can include a cleaved variant of the full-length heavy chain. This may be a situation where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering system). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (Lys447) in the Fc region may be present or may not be present. Unless otherwise indicated, the amino acid sequence of the heavy chain including the Fc region is represented herein as not containing C-terminal glycine-lysine dipeptide. In one aspect, the heavy chain including the Fc region as specified herein is included in the antibody according to the present invention, and the heavy chain includes other C-terminal glycine-lysine dipeptide (G446 and K447, EU numbering system). In one aspect, the heavy chain including the Fc region as specified herein is included in the antibody according to the present invention, and the heavy chain includes other C-terminal glycine residues (G446, according to EU index numbering). Unless otherwise indicated herein, the numbering of amino acid residues in Fc region or constant region is carried out according to EU numbering system (also referred to as EU index), as described by Kabat et al. (Sequences of Proteins of Immunological Interest, 5th edition Public Health Service, National Institutes of Health, Bethesda, MD, 1991) (see also above).

[0148] "Framework" or "FR" refers to the variable domain residues excluding the complementarity determining regions (CDRs). The FR of a variable domain is usually composed of the following four FR domains: FR1, FR2, FR3, and FR4. Therefore, CDR and FR sequences usually appear in the following sequence in VH (or VL): FR1-CDR-H1 (CDR-L1)-FR2-CDR-H2 (CDR-L2)-FR3-CDR-H3 (CDR-L3)-FR4.

[0149] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0150] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived from the primary transformed cell, regardless of the number of passages. Progeny may not be identical to the nucleic acid content of the parent cell, but may contain mutations. Mutant progeny as screened or selected for the same function or biological activity as in the original transformed cell are included herein.

[0151] A "human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human antibody using a full repertoire of human antibodies or other human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.

[0152] A "human consensus framework" is a framework that represents the amino acid residues that are most commonly present in a selection of human immunoglobulin VL or VH framework sequences. In general, the selection of human immunoglobulin VL or VH sequences is from a subset of variable domain sequences. In general, the subset of sequences is a subset as described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one aspect, for VL, the subgroup is subgroup κI as in Kabat et al., supra. In one aspect, for VH, the subgroup is subgroup III as in Kabat et al., supra. [[Adjust as necessary to refer to the actual subgroup of VH / VL of the present invention]]

[0153] "Humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain aspects, a humanized antibody will comprise substantially all of at least one, usually two variable domains, wherein all or substantially all of the CDRs correspond to the CDRs of non-human antibodies, and all or substantially all of the FRs correspond to the FRs of human antibodies. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. An antibody in "humanized form", such as a non-human antibody, refers to an antibody that has undergone humanization.

[0154] As used herein, the term "hypervariable region" or "HVR" refers to individual regions of an antibody variable domain that are hypervariable in sequence and determine antigen binding specificity, such as the "complementarity determining region" ("CDR").

[0155] Typically, antibodies contain six CDRs; three in VH (HCDR1, HCDR2, HCDR3) and three in VL (LCDR1, LCDR2, LCDR3). Herein, exemplary CDRs include:

[0156] (a) hypervariable loops occurring at the following amino acid residues: 26 to 32 (L1), 50 to 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2), and 96 to 101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0157] (b) CDRs occurring at amino acid residues 24 to 34 (L1), 50 to 56 (L2), 89 to 97 (L3), 31 to 35b (H1), 50 to 65 (H2), and 95 to 102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0158] (c) Antigenic contact points occur at the following amino acid residues: 27c to 36 (L1), 46 to 55 (L2), 89 to 96 (L3), 30 to 35b (H1), 47 to 58 (H2), and 93 to 101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)).

[0159] Unless otherwise indicated, CDRs are determined according to the method described in Kabat et al., supra. One skilled in the art will appreciate that CDR names may also be determined according to the method described in Chothia, supra, the method described in McCallum, supra, or any other scientifically accepted naming system.

[0160] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to a cytotoxic agent.

[0161] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, an individual or subject is a human.

[0162] An "isolated" antibody is one that has been separated from a component of its natural environment. In some aspects, the antibody is purified to a purity greater than 95% or 99% as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0163] The term "nucleic acid molecule" or "polynucleotide" includes any compound and / or substance comprising a nucleotide polymer. Each nucleotide is composed of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose) and a phosphate group. Typically, nucleic acid molecules are described by base sequences, wherein the bases represent the primary structure (linear structure) of the nucleic acid molecule. The base sequence is generally expressed as from 5' to 3'. In this article, the term nucleic acid molecule encompasses synthetic forms of deoxyribonucleic acid (DNA) (including, for example, complementary DNA (cDNA) and genomic DNA), ribonucleic acid (RNA) (particularly messenger RNA (mRNA)), DNA or RNA, and mixed polymers comprising two or more of these molecules. Nucleic acid molecules can be linear or cyclic. In addition, the term nucleic acid molecule includes sense strands and antisense strands, as well as single-stranded and double-stranded forms. In addition, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivative sugars, phosphate backbone bonds or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as carriers for direct expression in vitro and / or in vivo (e.g., in a host or patient) of the antibodies of the present invention. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA may be chemically modified to enhance the stability of the RNA vector and / or the expression of the coding molecule so that mRNA may be injected into a subject to produce antibodies in vivo (see, e.g., Stadler et al., Nature Medicine 2017, published online on June 12, 2017, doi:10.1038 / nm.4356 or EP 2 101 823 B1).

[0164] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0165] "Isolated nucleic acid encoding a polypeptide" refers to one or more nucleic acid molecules encoding, for example, antibody heavy and light chains (or fragments thereof) or idiotype-specific polypeptides, including these nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules are present at one or more locations in a host cell.

[0166] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies comprising the population are identical and / or bind to the same epitope, except for possible variant antibodies, such as those containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, which are usually present in small amounts. In contrast to polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed to a single determinant on an antigen. Therefore, the modifier "monoclonal" indicates that the characteristic of an antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibodies to be produced by any particular method. For example, monoclonal antibodies according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus, and such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0167] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical compositions.

[0168] "Native antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains that are disulfide bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also known as a variable heavy chain domain or a heavy chain variable region, followed by three constant heavy chain domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also known as a variable light chain domain or a light chain variable region, followed by a constant light chain (CL) domain.

[0169] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0170] "Amino acid sequence identity percentage (%)" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing spaces (if necessary) to achieve maximum sequence identity percentage, and for the purpose of alignment without considering any conservative substitutions as components of sequence identity. Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or FASTA program package. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate identity percentage values. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc. and the source code has been filed with user documentation in the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087 and is described in WO 2001 / 007611.

[0171] Unless otherwise indicated, for the purposes of this paper, the values ​​of amino acid sequence identity percentages are generated using the BLOSUM50 comparison matrix using the ggsearch program of the FASTA package version 36.3.8c or higher. The FASTA package is by W.R. Pearson and D.J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; W.R. Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227-258; and Pearson et al., (1997) Genomics 46:24-36 creation and available from the following public: www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, the public server accessed through fasta.bioch.virginia.edu / fasta_www2 / index.cgi can be used, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open:-10; ext:-2; Ktup=2) to ensure that a global rather than a local alignment is performed. The amino acid identity percentage is given in the output alignment header.

[0172] The term "pharmaceutical composition" or "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the pharmaceutical composition would be administered.

[0173] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition or formulation other than the active ingredient, which is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0174] Unless otherwise indicated, the term "FoR1" or "folate receptor 1" as used herein refers to any native FolR1 from any vertebrate source, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length," unprocessed FolR1, as well as any form of FolR1 produced by processing in a cell. The term also encompasses naturally occurring variants of FolR1, such as splice variants or allelic variants.

[0175] As used herein, "treatment" (and grammatical variants thereof such as treat or treat) refers to an attempt to alter the natural course of the disease in the individual being treated, and may be performed for prevention or clinical interventions that may be performed during clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some aspects, the antibodies of the invention are used to delay the development of a disease or slow the progression of a disease.

[0176] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that participates in the binding of an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007).) A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, antibodies that bind to a specific antigen can be isolated using the VH or VL domains from antibodies that bind to the antigen, respectively, to screen for libraries of complementary VL or VH domains. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).

[0177] The term "vector" as used herein refers to a nucleic acid molecule capable of carrying another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."

[0178] As used herein, the term "antigen binding portion" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, the antigen binding portion is capable of directing the entity to which it is connected (e.g., a second antigen binding portion) to a target site, such as a tumor cell or tumor stroma of a specific type with an antigenic determinant. In another embodiment, the antigen binding portion is capable of activating signal transduction by its target antigen (e.g., a T cell receptor complex antigen). The antigen binding portion includes antibodies and fragments thereof as further defined herein. A specific antigen binding portion includes an antigen binding domain of an antibody, which includes an antibody heavy chain variable region and an antibody light chain variable region. In certain embodiments, the antigen binding portion may include an antibody constant region as further defined herein and known in the art. Available heavy chain constant regions include any of the following five isotypes: α, δ, ε, γ, or μ. Available light chain constant regions include any of the following two isotypes: κ and λ.

[0179] As used herein, "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity and expression of activation markers. The protease-activatable "T cell activation bispecific molecules" of the present invention are capable of inducing T cell activation. Suitable assays for measuring T cell activation are known in the art as described herein.

[0180] As used herein, "target cell antigen" refers to an antigenic determinant present on the surface of a target cell, for example, a cell in a tumor (such as a cancer cell or a cell of a tumor stroma).

[0181] As used herein, the terms "first" and "second" with respect to antigen binding moieties and the like are used for convenience in distinguishing when there is more than one of each type of moiety. Unless explicitly stated, the use of these terms is not intended to confer a particular order or orientation on the protease-activatable T cell activating bispecific molecules.

[0182] "Fab molecule" refers to a protein composed of the VH and CH1 domains of the heavy chain ("Fab heavy chain") and the VL and CL domains of the light chain ("Fab light chain") of an immunoglobulin.

[0183] "Fusion" means that the components (eg, Fab molecule and Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.

[0184] As used herein, the term "single chain" refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In certain embodiments, one of the antigen binding moieties is a single-chain Fab molecule, i.e., a Fab molecule in which a Fab light chain and a Fab heavy chain are connected by a peptide linker to form a single peptide chain. In a specific embodiment of this type, the C-terminus of the Fab light chain in the single-chain Fab molecule is connected to the N-terminus of the Fab heavy chain.

[0185] "Cross" Fab molecules (also referred to as "Crossfab") refer to a Fab molecule in which the variable regions or constant regions of the Fab heavy and light chains are exchanged, i.e., the cross-Fab molecule comprises a peptide chain consisting of a light chain variable region and a heavy chain constant region, and a peptide chain consisting of a heavy chain variable region and a light chain constant region. For clarity, in a cross-Fab molecule in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant region is referred to herein as the "heavy chain" of the cross-Fab molecule. Conversely, in a cross-Fab molecule in which the constant regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain variable region is referred to herein as the "heavy chain" of the cross-Fab molecule.

[0186] In contrast, a "conventional" Fab molecule refers to a Fab molecule in its native form, ie, comprising a heavy chain consisting of a heavy chain variable region and a constant region (VH-CH1), and a light chain consisting of a light chain variable region and a constant region (VL-CL).

[0187] As used herein, "idiotype-specific polypeptide" refers to a polypeptide that recognizes the idiotype of an antigen binding portion (e.g., an antigen binding portion that is specific for CD3). "Idiotype" can be defined as a specific combination of idiotopes present within the complementarity determining regions (CDRs) of an antigen binding portion. Idiotype-specific polypeptides are capable of specifically binding to the variable region of an antigen binding portion, thereby reducing or preventing the specific binding of the antigen binding portion to its cognate antigen. When bound to a molecule comprising an antigen binding portion, the idiotype-specific polypeptide can act as a masking portion of the molecule. Anti-idiotype antibodies or anti-idiotype binding antibody fragments that are specific for the idiotype of an anti-CD3 binding molecule are specifically disclosed herein.

[0188] As used herein, "protease" or "proteolytic enzyme" refers to any proteolytic enzyme that cuts a linker at a recognition site and is expressed by a target cell. Such proteases may be secreted by the target cell or remain associated with the target cell, for example, on the surface of the target cell. Examples of proteases include, but are not limited to, metalloproteinases (e.g., matrix metalloproteinases 1 to 28, disintegrin metalloproteinases (ADAM) 2, 7 to 12, 15, 17 to 23, 28 to 30, and 33), serine proteases (e.g., urokinase-type plasminogen activator and matriptase), cysteine ​​proteases, aspartic proteases, and members of the cathepsin family.

[0189] As used herein, "protease activatable" with respect to T cell activating bispecific molecules refers to T cell activating bispecific molecules that have reduced or eliminated ability to activate T cells due to a masking moiety that reduces or eliminates the ability of the T cell activating bispecific molecule to bind to CD3. Upon dissociation of the masking moiety by proteolytic cleavage (e.g., by proteolytic cleavage of a linker that links the masking moiety to the T cell activating bispecific molecule), binding to CD3 is restored, thereby activating the T cell activating bispecific molecule.

[0190] As used herein, "reversibly sequestering" refers to masking the binding of a moiety or idiotype-specific polypeptide to an antigen-binding moiety or molecule, such as to prevent the antigen-binding moiety or molecule from binding to its antigen (e.g., CD3). Such sequestration is reversible because the idiotype-specific polypeptide can be released from the antigen-binding moiety or molecule, such as by protease cleavage, thereby releasing the antigen-binding moiety or molecule to bind to its antigen.

[0191] Protease-activatable T cell-activating bispecific molecules

[0192] The present invention provides improved T cell activation bispecific molecules. In particular, the present invention provides protease-activatable T cell activation bispecific molecules that have reduced or non-existent activity before reaching the site of action, such as, for example, the tumor microenvironment. This allows for improved safety, such as lower toxicity and effective activation of molecules at the site of action.

[0193] In one aspect, the invention relates to a protease-activatable T cell activating bispecific molecule comprising

[0194] 1. a first antigen binding portion that is capable of binding to CD3;

[0195] 2. a second antigen binding moiety capable of binding to a target cell antigen; and

[0196] 3. A masking moiety covalently linked to the T cell bispecific binding molecule via a protease-cleavable linker, wherein the masking moiety is capable of binding to the idiotype of the first antigen binding moiety or the second antigen binding moiety, thereby reversibly concealing the first antigen binding moiety or the second antigen binding moiety.

[0197] The first antigen binding moiety capable of binding to CD3 comprises an idiotype. In one embodiment, the masking portion of the protease-activatable T cell activation bispecific molecule is covalently attached to the first antigen binding moiety. In one embodiment, the masking portion is covalently attached to the heavy chain variable region of the first antigen binding moiety. In one embodiment, the masking portion is covalently attached to the light chain variable region of the first antigen binding moiety. The covalent bond and the specific binding (preferably non-covalent binding) of the masking portion to the idiotype first antigen binding site are separate. The idiotype of the first antigen binding moiety comprises its variable region. In one embodiment, when the first antigen binding moiety binds to CD3, the masking portion binds to the amino acid residues contacting CD3. In a preferred embodiment, the masking portion is not a cognate antigen or a fragment thereof of the first antigen binding moiety, that is, the masking portion is not CD3 or a fragment thereof. In one embodiment, the masking portion is an anti-idiotype antibody or a fragment thereof. In one embodiment, the masking portion is an anti-idiotype scFv. Exemplary embodiments of the masking portion of the anti-idiotype scFv and the protease-activatable T cell activation molecule comprising such a masking portion are described in detail below and in the examples.

[0198] Exemplary Antigen Binding Moieties

[0199] The antigen binding molecules of the present invention are bispecific, that is, they include at least two antigen binding moieties that can specifically bind to two different antigenic determinants. According to the present invention, the antigen binding moiety is a Fab molecule (that is, an antigen binding domain consisting of a heavy chain and a light chain, wherein each chain includes a variable region and a constant region). In one embodiment, the Fab molecule is a human Fab molecule. In another embodiment, the Fab molecule is a humanized Fab molecule. In yet another embodiment, these Fab molecules include human heavy chain and light chain constant regions.

[0200] At least one antigen binding moiety in the antigen binding moiety is a cross Fab molecule. Such modifications prevent the mispairing of the heavy chain and light chain from different Fab molecules, thereby improving the productivity and purity of the recombinantly produced T cell activation bispecific molecule that can be activated by the protease of the present invention. In the specific cross Fab molecule that can be used for the T cell activation bispecific molecule that can be activated by the protease of the present invention, the constant region of the Fab light chain and the Fab heavy chain is exchanged. In another cross Fab molecule that can be used for the T cell activation bispecific molecule that can be activated by the protease of the present invention, the variable region of the Fab light chain and the Fab heavy chain is exchanged.

[0201] In a specific embodiment according to the present invention, the protease-activatable T cell activation bispecific molecule is capable of binding to a target cell antigen (particularly a tumor cell antigen) and CD3 simultaneously. In one embodiment, the protease-activatable T cell activation bispecific molecule is capable of cross-linking T cells and target cells by binding to a target cell antigen and CD3 simultaneously. In even more specific embodiments, such simultaneous binding results in the lysis of target cells (particularly tumor cells). In one embodiment, this simultaneous binding results in the activation of T cells. In other embodiments, this simultaneous binding results in a cellular response of T lymphocytes, particularly cytotoxic T lymphocytes, selected from the group consisting of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. In one embodiment, the protease-activatable T cell activation bispecific molecule binds to CD3 without simultaneously binding to a target cell antigen, and does not result in T cell activation.

[0202] In one embodiment, the protease-activatable T cell activating bispecific molecule is capable of redirecting the cytotoxic activity of T cells to target cells. In a specific embodiment, the redirection is independent of MHC-mediated peptide antigen presentation of the target cell and / or the specificity of the T cell.

[0203] In particular, the T cells according to any embodiment of the present invention are cytotoxic T cells. In some embodiments, the T cells are CD4 + or CD8 + T cells, especially CD8 + T cells.

[0204] CD3 binding part

[0205] The protease-activatable T cell activation bispecific molecule of the present invention comprises at least one antigen binding portion capable of binding to CD3 (also referred to herein as "CD3 antigen binding portion" or "first antigen binding portion"). In a specific embodiment, the protease-activatable T cell activation bispecific molecule comprises no more than one antigen binding portion capable of binding to CD3. In one embodiment, the protease-activatable T cell activation bispecific molecule provides monovalent binding to CD3. CD3 antigen binding is a crossover Fab molecule, that is, a Fab molecule in which the variable or constant regions of the Fab heavy and light chains are exchanged. In embodiments in which there is more than one antigen binding portion capable of binding to a target cell antigen contained in the protease-activatable T cell activation bispecific molecule, the antigen binding portion capable of binding to CD3 is preferably a crossover Fab molecule, and the antigen binding portion capable of binding to the target cell antigen is a conventional Fab molecule.

[0206] In a specific embodiment, CD3 is human CD3 or cynomolgus CD3, most particularly human CD3. In a specific embodiment, the CD3 antigen binding portion cross-reacts with (i.e., specifically binds to) human and cynomolgus CD3. In some embodiments, the first antigen binding portion is capable of binding to the epsilon subunit of CD3.

[0207] The CD3 antigen binding portion comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9.

[0208] In a preferred embodiment, the CD3 antigen binding portion comprises the heavy chain CDR1 of SEQ ID NO:1, the heavy chain CDR2 of SEQ ID NO:2, the heavy chain CDR3 of SEQ ID NO:3, the light chain CDR1 of SEQ ID NO:7, the light chain CDR2 of SEQ ID NO:8 and the light chain CDR3 of SEQ ID NO:9.

[0209] In one embodiment, the CD3 antigen binding portion comprises: a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5; and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10.

[0210] In a preferred embodiment, the CD3 antigen binding portion comprises the heavy chain variable region sequence of SEQ ID NO:5 and the light chain variable region sequence of SEQ ID NO:10.

[0211] In one embodiment, the CD3 antigen binding portion comprises a heavy chain CDR1 of SEQ ID NO:1, a heavy chain CDR2 of SEQ ID NO:2, a heavy chain CDR3 of SEQ ID NO:4, a light chain CDR1 of SEQ ID NO:7, a light chain CDR2 of SEQ ID NO:8, and a light chain CDR3 of SEQ ID NO:9.

[0212] In one embodiment, the CD3 antigen binding portion comprises: a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:6; and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10.

[0213] In one embodiment, the CD3 antigen binding portion comprises the heavy chain variable region sequence of SEQ ID NO:6 and the light chain variable region sequence of SEQ ID NO:10.

[0214] Target cell antigen binding moiety

[0215] The protease-activatable T cell activation bispecific molecule of the present invention comprises at least one antigen binding portion capable of binding to a target cell antigen (also referred to herein as a "target cell antigen binding portion" or a "second" or "third" antigen binding portion). In certain embodiments, the protease-activatable T cell activation bispecific molecule comprises two antigen binding portions capable of binding to a target cell antigen. In a specific such embodiment, each of these antigen binding portions specifically binds to the same antigenic determinant. In an even more specific embodiment, all of these antigen binding portions are the same. In one embodiment, the protease-activatable T cell activation bispecific molecule comprises an immunoglobulin molecule capable of binding to a target cell antigen. In one embodiment, the protease-activatable T cell activation bispecific molecule comprises no more than two antigen binding portions capable of binding to a target cell antigen.

[0216] In a preferred embodiment, the target cell antigen binding portion is a Fab molecule, in particular a conventional Fab molecule that binds to a specific antigenic determinant and is capable of directing the protease-activatable T cell activating bispecific molecule to a target site (e.g., to a specific type of tumor cell carrying the antigenic determinant).

[0217] In certain embodiments, the target cell antigen binding moiety specifically binds to a cell surface antigen. In a particular embodiment, the target cell antigen binding moiety specifically binds to folate receptor 1 (FolR1) on the surface of a target cell.

[0218] In certain embodiments, the target cell antigen binding moiety is directed against an antigen associated with a pathological condition, such as an antigen presented on a tumor cell or on a cell infected by a virus. Suitable antigens are cell surface antigens, such as, but not limited to, cell surface receptors. In a particular embodiment, the antigen is a human antigen. In a specific embodiment, the target cell antigen is folate receptor 1 (FolR1).

[0219] In a specific embodiment, the protease-activatable T cell activating bispecific molecule comprises at least one antigen binding portion that is specific for FolR1. In one embodiment, FolR1 is human FolR1. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises at least one antigen binding portion that is specific for human FolR1 and does not bind to human FolR2 or human FolR3. In one embodiment, the antigen binding portion that is specific for FolR1 comprises at least one heavy chain complementary determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

[0220] In one embodiment, the antigen binding portion specific for FolR1 comprises the heavy chain CDR1 of SEQ ID NO:11, the heavy chain CDR2 of SEQ ID NO:12, the heavy chain CDR3 of SEQ ID NO:13, the light chain CDR1 of SEQ ID NO:7, the light chain CDR2 of SEQ ID NO:8, and the light chain CDR3 of SEQ ID NO:9.

[0221] In yet another embodiment, the antigen binding portion that is specific for FolR1 comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 14 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 10, or variants thereof that retain functionality.

[0222] In one embodiment, the antigen binding portion specific for FolR1 comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:14; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:10.

[0223] Masking part

[0224] The protease-activatable T cell activation bispecific molecule of the present invention comprises at least one masking part. Others have attempted to mask the binding of antibodies by capping the binding part with an antigen fragment recognized by the binding part (e.g., WO2013128194). This method has several limitations. For example, the flexibility of using antigens to reduce the affinity of the binding part is low. This is because the affinity must be high enough to be reliably masked by the antigen mask. In addition, the dissociated antigen may bind and interact with its cognate receptor in vivo and produce undesirable signals to cells expressing such receptors. In contrast, the method described herein uses anti-idiotypic antibodies or fragments thereof as masks. Two competing considerations for designing an effective masking part are 1. the effectiveness of masking and 2. the reversibility of masking. If the affinity is too low, the masking will be inefficient. However, if the affinity is too high, the masking process may not be easily reversed. It is impossible to predict whether a high-affinity anti-idiotypic mask or a low-affinity anti-idiotypic mask will work better. As described herein, higher affinity masking moieties are generally better at masking the antigen binding side while being effectively removed to activate the molecule. In one embodiment, the anti-idiotypic mask has a KD of 1 to 8 nM. In one embodiment, the anti-idiotypic mask has a KD of 2 nM at 37°C. In a specific embodiment, the masking moiety recognizes the idiotype of a first antigen binding moiety that is capable of binding to CD3 (e.g., human CD3). In a specific embodiment, the masking moiety recognizes the idiotype of a second antigen binding moiety that is capable of binding to a target cell antigen.

[0225] In one embodiment, the masking portion masks the CD3 binding portion and comprises at least one of the following: heavy chain complementary determining region (HCDR) 1 of SEQ ID NO: 15, HCDR2 of SEQ ID NO: 16, HCDR2 of SEQ ID NO: 17, HCDR2 of SEQ ID NO: 18, HCDR3 of SEQ ID NO: 19, light chain complementary determining region (LCDR) 1 of SEQ ID NO: 23, LCDR1 of SEQ ID NO: 26, LCDR2 of SEQ ID NO: 27, LCDR3 of SEQ ID NO: 28, and LCDR3 of SEQ ID NO: 29.

[0226] In one embodiment, the masking portion comprises: a VH region comprising a HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), a HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16), and a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising a LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25), a LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27), and a LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0227] In one embodiment, the masking portion comprises: a VH region comprising a HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), a HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16), and a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising a LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26), a LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27), and a LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0228] In a more preferred embodiment, the masking portion comprises: a VH region comprising a HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), a HCDR2 amino acid sequence of WINTETGEPRYTDDFTG (SEQ ID NO: 17), and a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising a LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26), a LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27), and a LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0229] In one embodiment, the masking portion comprises: a VH region comprising a HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), a HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18), and a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising a LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26), a LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27), and a LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0230] In one embodiment, the masking portion comprises: a VH region comprising a HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), a HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18), and a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising a LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25), a LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27), and a LCDR3 amino acid sequence of QQSREFPYT (SEQ ID NO: 29).

[0231] In one embodiment, the masking moiety masks the CD3 binding moiety and comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 20. In one embodiment, the masking moiety masks the CD3 binding moiety and comprises a polypeptide sequence of SEQ ID NO: 30.

[0232] In a preferred embodiment, the masking moiety is humanized. Methods for humanizing immunoglobulins are well known in the art and described herein. Humanized masking moieties H1L1, H1L2, H2L2, H3L2, H3L3, and H7L5 are provided herein. The corresponding sequences are provided below.

[0233] In one embodiment, the masking portion comprises: a heavy chain variable (VH) region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24; and a light chain variable (VL) region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34.

[0234] In one embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:21 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:31.

[0235] In a preferred embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:21 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:32.

[0236] In one embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:22 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:32.

[0237] In one embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:23 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:32.

[0238] In one embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:23 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:33.

[0239] In one embodiment, the masking portion comprises a VH region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:24 and a VL region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:34.

[0240] In one embodiment, the masking moiety or idiotype-specific polypeptide for reversibly concealing the antigen binding of the antigen binding molecule is a scFc. Such idiotype-specific polypeptide for reversibly concealing the anti-CD3 antigen binding site must be able to bind to the idiotype of the anti-CD3 antigen binding site, thereby reducing or eliminating the binding of the anti-CD3 antigen binding site to CD3. In one embodiment, the idiotype scF.

[0241] In one embodiment, the masking moiety comprises an idiotype-specific polypeptide for reversibly concealing antigen binding of the molecule. In one embodiment, the masking moiety comprises an idiotype-specific polypeptide. In a preferred embodiment, the idiotype-specific polypeptide is a scFv. In a preferred embodiment, the masking moiety is a scFv.

[0242] In a preferred embodiment, the scFv comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 35. In one embodiment, the anti-idiotypic scFv comprises the polypeptide sequence of SEQ ID NO:35.

[0243] In one embodiment, the scFv comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36. In a preferred embodiment, the anti-idiotypic scFv comprises the polypeptide sequence of SEQ ID NO:36.

[0244] In one embodiment, the scFv comprises a polypeptide sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 37. In one embodiment, the anti-idiotypic scFv comprises the polypeptide sequence of SEQ ID NO:37.

[0245] In one embodiment, the scFv comprises a polypeptide sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 38. In one embodiment, the anti-idiotypic scFv comprises the polypeptide sequence of SEQ ID NO:38.

[0246] Protease cleavable linker

[0247] The protease-activatable T cell activation bispecific molecule of the present invention comprises at least one protease-activatable linker. Preferably, the protease-activatable T cell activation bispecific molecule of the present invention is inactive before the protease-activatable linker cleavage, for example, in a tumor microenvironment. In one embodiment, the masking portion (e.g., idiotype-specific polypeptide) is covalently attached to the molecule via a linker. In one embodiment, the idiotype-specific polypeptide is covalently attached to the molecule via more than one linker. In one embodiment, the idiotype-specific polypeptide is covalently attached to the molecule via two linkers. In one embodiment, the linker is a peptide linker. In one embodiment, the linker is a protease-cleavable linker.

[0248] In one embodiment, the protease-cleavable linker comprises a protease recognition site. In one embodiment, the protease is a proteinase. In a preferred embodiment, the protease-cleavable linker comprises a proteinase recognition site.

[0249] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a linker having a protease recognition site, wherein the protease recognition site comprises the polypeptide sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P). In one embodiment, the protease recognition site comprises the polypeptide sequence of HQARK (SEQ ID NO: 43). In a preferred embodiment, the protease recognition site comprises the polypeptide sequence of PQARK (SEQ ID NO: 41).

[0250] PQARK (SEQ ID NO: 41) and HQARK (SEQ ID NO: 43) are protease recognition sites with advantageous and surprising properties. Ideally, a protease-activatable (therapeutic) molecule should be inactive before reaching the site of action (e.g., a tumor). An advantageous property of the protease recognition sites of the invention (e.g., PQARK and HQARK) is that they are stable in vivo before reaching the site of action (see, e.g., Figure 3 ). In addition, such activatable molecules should be effectively activated at the site of action (e.g., tumor). It is well known that the tumor microenvironment may exhibit a pH as low as 5.6 compared to the physiological pH value (about pH 7.4) (see, e.g., Boedtkjer et al., 2020, Annual Review of Physiology, Vol. 82, 2020, pp. 103-126).

[0251] Importantly, the protease recognition sites of the invention (e.g., PQARK and HQARK) can be more strongly activated at physiological pH than the published protease recognition site PMAKK (see, e.g., Table 4). Surprisingly, the protease recognition sites of the invention (e.g., PQARK and FOLR1 proTCB P035.093 HQARK 4.24.72 heavy chain 2P1AF5419) can be strongly activated at a pH as low as pH 5.6.

[0252] In one embodiment, the protease recognition site is embedded in a linker such as a (unstructured) polypeptide. In one embodiment, the polypeptide comprises one or more unstructured peptide linkers. In one embodiment, the isolated polypeptide comprises at least one peptide linker, particularly wherein the at least one peptide linker does not exhibit secondary structure. In one embodiment, the peptide comprises an amino acid sequence of at least 5 amino acids, preferably 5 to 100, more preferably 10 to 50 amino acids, most preferably 20 to 40 amino acids in length.

[0253] In one embodiment, the protease cleavable linker is a polypeptide having a length of 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 amino acids. In a preferred embodiment, the protease cleavable linker is a peptide having a length of 33 amino acids. In one embodiment, the polypeptide comprises a protease recognition site. In one embodiment, the protease recognition sequence is a substrate for a protease. In one embodiment, the protease recognition site comprises or consists of the sequence PQARK (SEQ ID NO:41) or HQARK (SEQ ID NO:43).

[0254] In one embodiment, the protease-cleavable linker is an unstructured polypeptide. In one embodiment, the protease-cleavable linker does not exhibit a secondary structure. In one embodiment, the protease-cleavable linker comprises at least one linker that promotes unstructured confirmation. In one embodiment, the linker comprises serine (S) and / or glycine (G). In one embodiment, at least one linker of the protease-cleavable linker comprises an amino acid sequence (GxS)n or (GxS)nGm, wherein G=glycine, S=serine, and (x=3, n=3, 4, 5 or 6, and m=0, 1, 2 or 3) or (x=4, n=2, 3, 4 or 5, and m=0, 1, 2 or 3), preferably x=4 and n=2 or 3, more preferably x=4 and n=2. In one embodiment, the protease-cleavable linker comprises (G4S)2. In one embodiment, the protease-cleavable linker comprises (G4S)3. In one embodiment, the protease-cleavable linker comprises G2S. The protease-cleavable linker comprises a protease recognition site at any position (e.g., the start, any position within or at the end of the linker).

[0255] In one embodiment, the isolated polypeptide comprises the sequence

[0256] SGGGSGGGGSPQARKGGGGSGGGGSGGGGSGGS (SEQ ID NO: 42) or consisting thereof. In one embodiment, the isolated polypeptide comprises the sequence

[0257] SGGGSGGGGSHQARKGGGGSGGGGSGGGGSGGS (SEQ ID NO: 44) or consisting thereof.

[0258] Protease-activatable T cell activating bispecific molecule format

[0259] The components of the protease-activatable T cell activating bispecific molecule can be fused to each other in a variety of configurations. Exemplary configurations are Figure 1 Depicted.

[0260] In certain embodiments, the protease-activatable T cell activating bispecific molecule comprises an Fc domain consisting of a first subunit and a second subunit capable of stably associating. In some embodiments, the second antigen binding moiety is fused to the N-terminus of the first subunit or the second subunit of the Fc domain at the C-terminus of the Fab heavy chain.

[0261] In one such embodiment, the first antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the second antigen binding moiety at the C-terminus of the Fab heavy chain. In a specific such embodiment, the protease-activatable T cell activating bispecific molecule consists essentially of the first antigen binding moiety and the second antigen binding moiety, an Fc domain consisting of a first subunit and a second subunit, and optionally one or more peptide linkers, wherein the first antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the second antigen binding moiety at the C-terminus of the Fab heavy chain, and the second antigen binding moiety is fused to the N-terminus of the first subunit or the second subunit of the Fc domain at the C-terminus of the Fab heavy chain. In addition, optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may be fused to each other.

[0262] In another such embodiment, the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit or the second subunit of the Fc domain. In a specific such embodiment, the protease-activatable T cell activating bispecific molecule consists essentially of a first antigen binding moiety and a second antigen binding moiety, an Fc domain consisting of the first subunit and the second subunit, and optionally one or more peptide linkers, wherein the first antigen binding moiety and the second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

[0263] In other embodiments, the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

[0264] In a specific embodiment, the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain. In a specific such embodiment, the protease-activatable T cell activating bispecific molecule consists essentially of the first antigen binding moiety and the second antigen binding moiety, an Fc domain consisting of a first subunit and a second subunit, and optionally one or more peptide linkers, wherein the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain, and the first antigen binding moiety is fused to the N-terminus of the first subunit or the second subunit of the Fc domain at the C-terminus of the Fab heavy chain. In addition, optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may be fused to each other.

[0265] The antigen binding moieties can be fused to the Fc domain or to each other directly or via a peptide linker comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n 、(SG4) n、(G4S) n or G4(SG4) n Peptide linker. "n" is typically a number between 1 and 10, typically between 2 and 4. A particularly suitable peptide linker for fusing the Fab light chains of the first antigen binding moiety and the second antigen binding moiety to each other is (G4S)2. In addition, the linker may comprise (a portion of) an immunoglobulin hinge region. In particular, at the N-terminus of the antigen binding moiety fused to the Fc domain subunit, the fusion may be via an immunoglobulin hinge region or a portion thereof, with or without an additional peptide linker.

[0266] Protease-activatable T cell activating bispecific molecules having a single antigen binding portion capable of binding to a target cell antigen are useful, particularly in cases where internalization of the target cell antigen is expected to occur following binding of a high affinity antigen binding portion. In such cases, the presence of more than one antigen binding portion specific for a target cell antigen may enhance internalization of the target cell antigen, thereby reducing its availability.

[0267] However, in many other situations it will be advantageous to have a protease-activatable T cell activating bispecific molecule comprising two or more antigen binding portions with specificity for target cell antigens, for example to optimize targeting to a target site or to cross-link a target cell antigen.

[0268] Therefore, in certain embodiments, the protease-activatable T cell activation bispecific molecule of the present invention further comprises a third antigen binding moiety, which is a Fab molecule capable of binding to a target cell antigen. In one embodiment, the third antigen binding moiety is a conventional Fab molecule. In one embodiment, the third antigen binding moiety can bind to the same target cell antigen as the second antigen binding moiety. In a specific embodiment, the first antigen binding moiety can bind to CD3, and the second antigen binding moiety and the third antigen binding moiety can bind to the target cell antigen. In a specific embodiment, the second antigen binding moiety and the third antigen binding moiety are identical (i.e., they comprise the same amino acid sequence).

[0269] In a specific embodiment, the first antigen binding portion is capable of binding to CD3, and the second antigen binding portion and the third antigen binding portion are capable of binding to FolR1, wherein the second antigen binding portion and the third antigen binding portion comprise at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

[0270] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises

[0271] (i) a first antigen binding portion, which is a Fab molecule capable of binding to CD3 and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9;

[0272] (ii) a second antigen binding portion which is a Fab molecule capable of binding to a target cell antigen.

[0273] In one embodiment, the first antigen binding portion comprises: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10.

[0274] In one embodiment, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:10.

[0275] In a specific embodiment, the second antigen binding portion is capable of binding to FolR1 and comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and at least one light chain CDR selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

[0276] In another specific embodiment, the second antigen binding portion is capable of binding to FolR1 and comprises: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0277] In one embodiment, the present invention provides a protease-activatable T cell activating bispecific molecule comprising

[0278] (i) a first antigen binding portion, which is a Fab molecule capable of binding to CD3, comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 30 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9;

[0279] (ii) a second antigen binding portion, which is a Fab molecule capable of specifically binding to FolR1 and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9.

[0280] In one embodiment, the present invention provides a protease-activatable T cell activating bispecific molecule comprising

[0281] (i) a first antigen binding portion, which is a Fab molecule capable of binding to CD3, comprising: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10,

[0282] (ii) a second antigen binding portion, which is a Fab molecule capable of binding to FolR1, comprising: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0283] In one embodiment, the second antigen binding moiety is a conventional Fab molecule.

[0284] In a specific embodiment, the first antigen binding moiety is a crossover Fab molecule, wherein the constant regions of the Fab light chain and the Fab heavy chain are exchanged, and the second antigen binding moiety is a conventional Fab molecule. In another specific embodiment, the first antigen binding moiety and the second antigen binding moiety are fused to each other, optionally, fused to each other via a peptide linker.

[0285] In certain embodiments, the protease-activatable T cell activating bispecific molecule further comprises an Fc domain composed of a first subunit and a second subunit capable of stably associating.

[0286] In another specific embodiment, no more than one antigen binding moiety capable of binding to CD3 is present in the protease-activatable T cell activating bispecific molecule (ie, the protease-activatable T cell activating bispecific molecule provides monovalent binding to CD3).

[0287] In a specific embodiment, the first antigen binding portion is capable of binding to CD3 and comprises at least one heavy chain complementary determining region (CDR) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9; and the second antigen binding portion and the third antigen binding portion are capable of binding to FolR1, wherein the second antigen binding portion and the third antigen binding portion comprise at least one heavy chain complementary determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

[0288] In a specific embodiment, the first antigen binding portion is capable of binding to CD3 and comprises at least one heavy chain complementary determining region (CDR) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9; and the second antigen binding portion and the third antigen binding portion are capable of binding to FolR1, wherein the second antigen binding portion and the third antigen binding portion comprise at least one heavy chain complementary determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 and at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

[0289] In a specific embodiment, the first antigen binding moiety is capable of binding to CD3 and comprises: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5, and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10, and the second antigen binding moiety and the third antigen binding moiety are capable of binding to FolR1, wherein the second antigen binding moiety and the third antigen binding moiety comprise: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:14, and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:10.

[0290] The second antigen binding portion and the third antigen binding portion can be fused to the Fc domain directly or through a peptide linker. In a specific embodiment, the second antigen binding portion and the third antigen binding portion are each fused to the Fc domain through an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region. In one embodiment, the second antigen binding portion and the third antigen binding portion and the Fc domain are part of an immunoglobulin molecule. In a specific embodiment, the immunoglobulin molecule is an IgG class immunoglobulin. In an even more specific embodiment, the immunoglobulin is an IgG1 subclass immunoglobulin. In another embodiment, the immunoglobulin is an IgG4 subclass immunoglobulin. In another specific embodiment, the immunoglobulin is a human immunoglobulin. In other embodiments, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin. In one embodiment, the protease-activatable T cell activating bispecific molecule essentially consists of an immunoglobulin molecule capable of binding to a target cell antigen and an antigen binding moiety capable of binding to CD3, wherein the antigen binding moiety is a Fab molecule, in particular a crossover Fab molecule, fused to the N-terminus of one of the immunoglobulin heavy chains, optionally via a peptide linker.

[0291] In a specific embodiment, the first antigen binding moiety and the third antigen binding moiety are each fused to the N-terminus of one of the subunits of the Fc domain at the C-terminus of the Fab heavy chain, and the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain. In a specific such embodiment, the protease-activatable T cell activating bispecific molecule consists essentially of the first antigen binding moiety, the second antigen binding moiety, the third antigen binding moiety, the Fc domain consisting of the first subunit and the second subunit, and optionally one or more peptide linkers, wherein the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain, and the first antigen binding moiety is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, and wherein the third antigen binding moiety is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain. In addition, optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may be fused to each other.

[0292] In one embodiment, the present invention provides a protease-activatable T cell activating bispecific molecule comprising

[0293] (i) a first antigen binding moiety which is a Fab molecule capable of binding to CD3, comprising a heavy chain complementary determining region (CDR) 1 of SEQ ID NO: 1, a heavy chain CDR 2 of SEQ ID NO: 2, a heavy chain CDR 3 of SEQ ID NO: 3, a light chain CDR 1 of SEQ ID NO: 7, a light chain SEQ ID NO: 8 and a light chain CDR 3 of SEQ ID NO: 9, wherein the first antigen binding moiety is a crossover Fab molecule in which the variable regions or constant regions, in particular the constant regions, of the Fab light chain and the Fab heavy chain are exchanged;

[0294] (ii) a second antigen-binding portion and a third antigen-binding portion, each of which is a Fab molecule capable of binding to FolR1, comprising heavy chain CDR 1 of SEQ ID NO: 11, heavy chain CDR2 of SEQ ID NO: 12, heavy chain CDR3 of SEQ ID NO: 13, light chain CDR 1 of SEQ ID NO: 7, light chain CDR 2 of SEQ ID NO: 8, and light chain CDR3 of SEQ ID NO: 9.

[0295] In one embodiment, the present invention provides a protease-activatable T cell activating bispecific molecule comprising

[0296] (i) a first antigen binding moiety, which is a Fab molecule capable of binding to CD3, comprising: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 5; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, wherein the first antigen binding moiety is a crossover Fab molecule, wherein the variable regions or constant regions, in particular the constant regions, of the Fab light chain and the Fab heavy chain are exchanged;

[0297] (ii) a second antigen binding portion and a third antigen binding portion, each of which is a Fab molecule capable of binding to FolR1, comprising: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14; and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0298] The protease-activatable T cell activating bispecific molecule according to any one of the above ten embodiments may further comprise (iii) an Fc domain composed of a first subunit and a second subunit capable of stably associating, wherein the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

[0299] In some protease-activatable T cell activating bispecific molecules of the present invention, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety are fused to each other, optionally via a linker peptide. Depending on the configuration of the first antigen binding moiety and the second antigen binding moiety, the Fab light chain of the first antigen binding moiety may be fused to the N-terminus of the Fab light chain of the second antigen binding moiety at its C-terminus, or the Fab light chain of the second antigen binding moiety may be fused to the N-terminus of the Fab light chain of the first antigen binding moiety at its C-terminus. The fusion of the Fab light chain of the first antigen binding moiety and the second antigen binding moiety further reduces the mispairing of the Fab heavy chain and the light chain, and also reduces the number of plasmids required to express some protease-activatable T cell activating bispecific molecules of the present invention.

[0300] In certain embodiments, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab light chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) -CH2-CH3(-CH4)); and polypeptides wherein the Fab heavy chain of the second antigen binding moiety shares a carboxyl-terminal peptide bond (VH (2) -CH1 (2) -CH2-CH3(-CH4)). In some embodiments, the protease-activatable T cell activating bispecific molecule further comprises: a polypeptide wherein the Fab heavy chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond (VH (1) -CL (1) ), and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0301] In an alternative embodiment, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab heavy chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (1) -CL (1) -CH2-CH3(-CH4)); and a polypeptide wherein the Fab heavy chain of the second antigen binding moiety shares a carboxyl-terminal peptide bond (VH (2) -CH1 (2) -CH2-CH3(-CH4)). In some embodiments, the protease-activatable T cell activating bispecific molecule further comprises: a polypeptide wherein the Fab light chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) ), and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0302] In some embodiments, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab light chain variable region of a first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the second antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) -VH (2) -CH1 (2) -CH2-CH3(-CH4)). In other embodiments, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab heavy chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the second antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (1) -CL (1) -VH (2) -CH1 (2) -CH2-CH3(-CH4)). In yet other embodiments, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab heavy chain of the second antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab light chain variable region of the first antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2) -VL (1) -CH1 (1)-CH2-CH3(-CH4)). In other embodiments, the protease-activatable T cell activating bispecific molecule comprises: a polypeptide wherein the Fab heavy chain of the second antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the first antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first antigen binding moiety (i.e., the first antigen binding moiety comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2) -VH (1) -CL (1) -CH2-CH3(-CH4)).

[0303] In some of these embodiments, the protease-activatable T cell activating bispecific molecule further comprises: a crossover Fab light chain polypeptide of the first antigen binding moiety, wherein the Fab heavy chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond (VH (1) -CL (1) ), and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) In other such embodiments, the protease-activatable T cell activating bispecific molecule further comprises: a crossover Fab light chain polypeptide, wherein the Fab light chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) ), and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) In yet other such embodiments, the protease-activatable T cell activating bispecific molecule further comprises: a polypeptide wherein the Fab light chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) -VL (2) -CL (2) ); a polypeptide wherein the Fab heavy chain variable region of the first antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first antigen binding moiety, which in turn shares a peptide bond with the Fab light chain polypeptide of the second antigen binding moiety (VH (1) -CL(1) -VL (2) -CL (2) ); a polypeptide wherein the Fab light chain polypeptide of the second antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab light chain variable region of the first antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond (VL (2) -CL (2) -VL (1) -CH1 (1) ); or a polypeptide, wherein the Fab light chain polypeptide of the second antigen binding moiety shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the first antigen binding moiety, which in turn shares a carboxyl-terminal peptide bond (VL (2) -CL (2) -VH (1) -CL (1) ).

[0304] The protease-activatable T cell activating bispecific molecule according to these embodiments may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide wherein the Fab heavy chain of the third antigen binding moiety shares a carboxyl-terminal peptide bond (VH) with the Fc domain subunit. (3) -CH1 (3) -CH2-CH3(-CH4)), and shares a carboxyl-terminal peptide bond (VL (3) -CL (3) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0305] According to any of the above embodiments, the components of the protease-activatable T cell activating bispecific molecule (e.g., antigen binding portion, Fc domain) can be fused directly or through various linkers, in particular through peptide linkers comprising one or more amino acids (usually about 2 to 20 amino acids) described herein or known in the art. Suitable non-immunogenic peptide linkers include, for example, (G4S) n 、(SG4) n 、(G4S) n or G4(SG4) n Peptide linkers, wherein "n" is generally a number between 1 and 10, usually between 2 and 4.

[0306] Fc domain

[0307] The Fc domain of the protease-activatable T cell activation bispecific molecule is composed of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises a CH2 and CH3 IgG heavy chain constant domain. The two subunits of the Fc domain can stably associate with each other. In one embodiment, the protease-activatable T cell activation bispecific molecule of the present invention comprises no more than one Fc domain.

[0308] In one embodiment according to the present invention, the Fc domain of the protease-activatable T cell activation bispecific molecule is an IgG Fc domain. In a specific embodiment, the Fc domain is an IgG1 Fc domain. In another embodiment, the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain is an IgG4 Fc domain, which comprises an amino acid substitution (Kabat numbering) at position S228, particularly an amino acid substitution S228P. The amino acid substitution reduces the in vivo Fab arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In another specific embodiment, the Fc domain is a human Fc domain.

[0309] Fc domain modifications that promote heterodimerization

[0310] The protease-activatable T cell activation bispecific molecules according to the present invention comprise different antigen binding moieties, which are fused to one or the other of the two subunits of the Fc domain, so that the two subunits of the Fc domain are generally contained in two different polypeptide chains. The recombinant co-expression of these polypeptides and the subsequent dimerization result in several possible combinations of the two polypeptides. In order to improve the yield and purity of the protease-activatable T cell activation bispecific molecules in recombinant production, it would be advantageous to introduce modifications that promote the association of the desired polypeptides into the Fc domain of the protease-activatable T cell activation bispecific molecules.

[0311] Therefore, in a specific embodiment, the Fc domain of the protease-activatable T cell activating bispecific molecule according to the present invention comprises a modification that promotes the association of the first subunit and the second subunit of the Fc domain. The most extensive protein-protein interaction site between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Therefore, in one embodiment, the modification is located in the CH3 domain of the Fc domain.

[0312] In a specific embodiment, the modification is a so-called "knob-into-hole" modification, which comprises a "knob" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain.

[0313] The knob-and-hole technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). In general, the method involves introducing a protrusion ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide, so that the protrusion can be positioned in the cavity to promote the formation of heterodimers and hinder the formation of homodimers. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity having the same or similar size as the protrusion is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine).

[0314] Thus, in a specific embodiment, in the CH3 domain of the first subunit of the Fc domain of the protease-activatable T cell activating bispecific molecule, an amino acid residue is replaced by an amino acid residue having a larger side chain volume, thereby generating a protrusion in the CH3 domain of the first subunit, and the protrusion can be positioned in the cavity in the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, an amino acid residue is replaced by an amino acid residue having a smaller side chain volume, thereby generating a cavity in the CH3 domain of the second subunit, and the protrusion in the CH3 domain of the first subunit can be positioned in the cavity.

[0315] Protrusions and cavities can be produced by altering the nucleic acid encoding the polypeptide (eg, by site-specific mutagenesis or by peptide synthesis).

[0316] In a specific embodiment, in the CH3 domain of the first subunit of the Fc domain, the threonine residue at position 366 is replaced by a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced by a valine residue (Y407V). In one embodiment, in addition, in the second subunit of the Fc domain, the threonine residue at position 366 is replaced by a serine residue (T366S), and the leucine residue at position 368 is replaced by an alanine residue (L368A).

[0317] In yet another embodiment, in addition in the first subunit of the Fc domain, the serine residue at position 354 is replaced by a cysteine ​​residue (S354C), and in addition in the second subunit of the Fc domain, the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C). The introduction of these two cysteine ​​residues results in the formation of a disulfide bridge between the two subunits of the Fc domain, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0318] In a specific embodiment, an antigen binding moiety capable of binding to CD3 (optionally via an antigen binding moiety capable of binding to a target cell antigen) is fused to the first subunit of the Fc domain (comprising a "knob" modification). Without wishing to be bound by theory, fusion of an antigen binding moiety capable of binding to CD3 to a knob-containing subunit of the Fc domain will (further) minimize the generation of antigen binding molecules comprising two antigen binding moieties capable of binding to CD3 (steric clash of two knob-containing polypeptides).

[0319] In an alternative embodiment, the modification that promotes the association of the first and second subunits of the Fc domain comprises a modification that mediates an electrostatic steering effect, such as described in PCT Publication WO 2009 / 089004. Typically, the method involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues such that homodimer formation becomes electrostatically unfavorable, but heterodimerization is electrostatically favorable.

[0320] Fc domain modifications that reduce Fc receptor binding and / or effector function

[0321] The Fc domain imparts favorable pharmacokinetic properties to protease-activatable T cell activation bispecific molecules, including a long serum half-life, which helps to obtain a good accumulation ratio and a favorable tissue-blood distribution ratio in the target tissue. However, at the same time, this may result in the undesirable targeting of protease-activatable T cell activation bispecific molecules to cells expressing Fc receptors, rather than targeting preferred cells with antigens. In addition, co-activation of Fc receptor signaling pathways may result in cytokine release, which, in combination with the T cell activation characteristics and long half-life of the antigen-binding molecules, leads to overactivation of cytokine receptors and serious side effects after systemic administration. Due to the potential destruction of T cells (e.g., by NK cells), the activation of immune cells (with Fc receptors) other than T cells may even reduce the efficacy of protease-activatable T cell activation bispecific molecules.

[0322] Thus, in a specific embodiment, the Fc domain of the protease-activatable T cell activating bispecific molecule according to the present invention exhibits reduced binding affinity to Fc receptors and / or reduced effector functions compared to a native IgG1 Fc domain. In one such embodiment, the Fc domain (or a protease-activatable T cell activating bispecific molecule comprising said Fc domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10%, and most preferably less than 5% of the binding affinity to Fc receptors compared to a native IgG1 Fc domain (or a protease-activatable T cell activating bispecific molecule comprising a native IgG1 Fc domain), and / or less than 50%, preferably less than 20%, more preferably less than 10%, and most preferably less than 5% of the effector functions compared to a native IgG1 Fc domain (or a protease-activatable T cell activating bispecific molecule comprising a native IgG1 Fc domain). In one embodiment, the Fc domain (or a protease-activatable T cell activating bispecific molecule comprising the Fc domain) does not substantially bind to an Fc receptor and / or induce effector functions. In a specific embodiment, the Fc receptor is an Fcγ receptor. In one embodiment, the Fc receptor is a human Fc receptor. In one embodiment, the Fc receptor is an activated Fc receptor. In a specific embodiment, the Fc receptor is an activated human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. In one embodiment, the effector function is one or more effector functions selected from the group of CDC, ADCC, ADCP and cytokine secretion. In a specific embodiment, the effector function is ADCC. In one embodiment, the Fc domain domain exhibits substantially similar binding affinity to a neonatal Fc receptor (FcRn) compared to a native IgG1 Fc domain domain. Substantially similar binding to FcRn is achieved when the Fc domain (or a protease-activatable T cell activating bispecific molecule comprising the Fc domain) exhibits greater than about 70%, particularly greater than about 80%, more particularly greater than about 90% of the binding affinity of a native IgG1 Fc domain (or a protease-activatable T cell activating bispecific molecule comprising a native IgG1 Fc domain) to FcRn.

[0323] In certain embodiments, the Fc domain is engineered to have a reduced binding affinity to Fc receptors and / or reduced effector functions compared to a non-engineered Fc domain. In a specific embodiment, the Fc domain of a protease-activatable T cell activation bispecific molecule comprises one or more amino acid mutations that reduce the binding affinity and / or effector functions of the Fc domain to Fc receptors. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one embodiment, the amino acid mutation reduces the binding affinity of the Fc domain to Fc receptors. In one embodiment, the amino acid mutation reduces the binding affinity of the Fc domain to Fc receptors by at least 2 times, at least 5 times, or at least 10 times. In embodiments where there is more than one amino acid mutation that reduces the binding affinity of the Fc domain to Fc receptors, the combination of these amino acid mutations can reduce the binding affinity of the Fc domain to Fc receptors by at least 10 times, at least 20 times, or even at least 50 times. In one embodiment, compared to a protease-activatable T cell activating bispecific molecule comprising a non-engineered Fc domain, a protease-activatable T cell activating bispecific molecule comprising an engineered Fc domain exhibits less than 20% of binding affinity to an Fc receptor, particularly less than 10%, more particularly less than 5%. In a specific embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activated Fc receptor. In a specific embodiment, the Fc receptor is an activated human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. Preferably, the binding to each of these receptors is reduced. In some embodiments, the binding affinity to complement components, particularly the binding affinity to C1q, is also reduced. In one embodiment, the binding affinity to the neonatal Fc receptor (FcRn) is not reduced. When the Fc domain (or a protease-activatable T cell activating bispecific molecule comprising the Fc domain) exhibits greater than about 70% of the binding affinity of a non-engineered form of the Fc domain (or a protease-activatable T cell activating bispecific molecule comprising the non-engineered form of the Fc domain) to FcRn, substantially similar binding to FcRn is achieved, i.e., the binding affinity of the Fc domain to the receptor is maintained. The Fc domain or a protease-activatable T cell activating bispecific molecule of the present invention comprising the Fc domain may exhibit such affinity greater than about 80% and even greater than about 90%. In certain embodiments, the Fc domain of the protease-activatable T cell activating bispecific molecule is engineered to have reduced effector function compared to a non-engineered Fc domain.The effector function of reduction may include but is not limited to one or more of the following items: reduced complement dependent cytotoxicity (CDC), reduced antibody dependent cell-mediated cytotoxicity (ADCC), reduced antibody dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen presenting cells to antigen uptake, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling induced apoptosis, reduced cross-linking of target binding antibodies, reduced dendritic cell maturation, or reduced T cell sensitization. In one embodiment, the effector function of reduction is selected from the group of reduced CDC, reduced ADCC, reduced ADCP and reduced cytokine secretion. In a specific embodiment, the effector function of reduction is reduced ADCC. In one embodiment, the reduced ADCC is less than 20% of the ADCC induced by the non-engineered Fc domain (or the protease-activatable T cell activation bispecific molecule comprising the non-engineered Fc domain).

[0324] In one embodiment, the amino acid mutation that reduces the binding affinity of the Fc domain to the Fc receptor and / or the effector function is an amino acid substitution. In one embodiment, the Fc domain is included in the amino acid substitution at the position selected from the group of E233, L234, L235, N297, P331 and P329. In a more specific embodiment, the Fc domain is included in the amino acid substitution at the position selected from the group of L234, L235 and P329. In some embodiments, the Fc domain includes the amino acid substitution L234A and L235A. In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In one embodiment, the Fc domain is included in the amino acid substitution at position P329. In a more specific embodiment, the amino acid substitution is P329A or P329G, particularly P329G. In one embodiment, the Fc domain is included in the amino acid substitution at position P329, and further amino acid substitutions at the position selected from E233, L234, L235, N297 and P331. In a more specific embodiment, the further amino acid substitution is E233P, L234A, L235A, L235E, N297A, N297D or P331S. In a specific embodiment, the Fc domain comprises amino acid substitutions at positions P329, L234 and L235. In a more specific embodiment, the Fc domain comprises amino acid mutations L234A, L235A and P329G ("P329GLALA"). In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. The "P329G LALA" combination of amino acid substitutions almost completely eliminates the Fc gamma receptor (and complement) binding of the human IgG1 Fc domain, as described in PCT Publication No. WO 2012 / 130831, which is incorporated herein by reference in its entirety. WO 2012 / 130831 also describes methods of making such mutant Fc domains and methods of determining their properties, such as Fc receptor binding or effector function.

[0325] Compared with IgG1 antibodies, IgG4 antibodies show reduced binding affinity to Fc receptors and reduced effector functions. Therefore, in some embodiments, the Fc domain of the protease-activatable T cell activation bispecific molecule of the present invention is an IgG4 Fc domain, particularly a human IgG4 Fc domain. In one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position S228, particularly an amino acid substitution S228P. In order to further reduce its binding affinity to Fc receptors and / or its effector functions, in one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position L235, particularly an amino acid substitution L235E. In another embodiment, the IgG4 Fc domain comprises an amino acid substitution at position P329, particularly an amino acid substitution P329G. In a specific embodiment, the IgG4 Fc domain comprises an amino acid substitution at positions S228, L235 and P329, particularly an amino acid substitution S228P, L235E and P329G. Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are described in PCT Publication No. WO 2012 / 130831, the entire contents of which are incorporated herein by reference.

[0326] In a specific embodiment, the Fc domain that exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain is a human IgG1 Fc domain comprising amino acid substitutions L234A, L235A and optionally P329G, or a human IgG4 Fc domain comprising amino acid substitutions S228P, L235E and optionally P329G.

[0327] In certain embodiments, N-glycosylation of the Fc domain has been eliminated. In one such embodiment, the Fc domain comprises an amino acid mutation at position N297, particularly an amino acid substitution replacing asparagine with alanine (N297A) or aspartic acid (N297D).

[0328] In addition to the Fc domains described above and in PCT Publication No. WO 2012 / 130831, Fc domains with reduced Fc receptor binding and / or reduced effector function also include those with mutations to one or more of Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutant, in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581).

[0329] Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods can include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The correct nucleotide changes can be verified, for example, by sequencing.

[0330] The binding to Fc receptors can be easily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard instruments (such as BIAcore instruments (GE Healthcare)), and Fc receptors such as can be obtained by recombinant expression. Suitable such binding assays are described herein. Alternatively, the binding affinity of the Fc domain or the cell-activated bispecific antigen binding molecules comprising the Fc domain to the Fc receptor can be evaluated using a cell line known to express a specific Fc receptor (such as human NK cells expressing FcγIIIa receptors).

[0331] The effector function of the T cell activation bispecific molecule that the Fc domain or the protease containing the Fc domain can activate can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for evaluating the ADCC activity of molecules of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays can be used (see, for example, ACTI for flow cytometry). TM Nonradioactive cytotoxicity assay (Cell Technology, Inc. Mountain View, CA); and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the target molecule can be assessed in vivo, for example, in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

[0332] In some embodiments, the binding of the Fc domain to complement components, particularly C1q, is reduced. Thus, in some embodiments, wherein the Fc domain is engineered to have reduced effector function, the reduced effector function includes reduced CDC. A C1q binding assay can be performed to determine whether the protease-activatable T cell activating bispecific molecule is able to bind to C1q and thus has CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

[0333] Exemplary protease-activatable T cell activating bispecific molecules capable of binding to CD3 and FolR1

[0334] The first antigen binding moiety capable of binding to CD3 as described above, the second antigen binding moiety capable of binding to FolR1 as described above, the Fc domain as described above, the masking moiety and the protease-cleavable linker of the present invention can be fused to each other in various configurations.

[0335] An exemplary configuration is Figure 1 Exemplary sequences are shown below.

[0336] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 48. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 48.

[0337] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 49. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 49.

[0338] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 50. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 50.

[0339] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 51. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 51.

[0340] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 52. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 52.

[0341] In one embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 53. In one embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 53.

[0342] In a preferred embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 54. In a more preferred embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 54.

[0343] In another preferred embodiment, the protease-activatable T cell activating bispecific molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 46, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 55. In a more preferred embodiment, the protease-activatable T cell activating bispecific molecule comprises the polypeptide sequence of SEQ ID NO: 45, the polypeptide sequence of SEQ ID NO: 46, and the polypeptide sequence of SEQ ID NO: 55.

[0344] Polynucleotide

[0345] The present invention further provides an isolated polynucleotide encoding a protease-activatable T cell activating bispecific molecule as described herein or a fragment thereof. In some embodiments, the fragment is an antigen binding fragment.

[0346] The polynucleotide encoding the protease-activatable T cell activation bispecific molecule of the present invention can be expressed as a single polynucleotide encoding the entire protease-activatable T cell activation bispecific molecule or as a plurality of (e.g., two or more) polynucleotides co-expressed. The polypeptide encoded by the co-expressed polynucleotide can be associated, for example, by a disulfide bond or other means, to form a protease-activatable T cell activation bispecific molecule. For example, the light chain portion of the antigen binding portion can be encoded by a polynucleotide separated from the portion of the protease-activatable T cell activation bispecific molecule, which comprises a heavy chain portion of the antigen binding portion, an Fc domain subunit, and an optional other Fab fragment (part). When co-expressed, the heavy chain polypeptide will associate with the light chain polypeptide to form an antigen binding portion. In another example, a portion of a protease-activatable T cell activation bispecific molecule comprising one of the two Fc domain subunits and optionally one or more Fab molecules (parts) can be encoded by a polynucleotide separated from the portion of the protease-activatable T cell activation bispecific molecule comprising another of the two Fc domain subunits and an optional antigen binding portion (part). When co-expressed, the Fc domain subunits will associate to form an Fc domain.

[0347] In some embodiments, the isolated polynucleotide encodes the entire protease-activatable T cell activation bispecific molecule according to the present invention as described herein. In other embodiments, the isolated polynucleotide encodes the polypeptide contained in the protease-activatable T cell activation bispecific molecule according to the present invention as described herein.

[0348] In another embodiment, the present invention relates to an isolated polynucleotide encoding a protease-activatable T cell activating bispecific molecule of the present invention or a fragment thereof, wherein the polynucleotide comprises a sequence encoding a variable region sequence. In another embodiment, the present invention relates to an isolated polynucleotide encoding a protease-activatable T cell activating bispecific molecule or a fragment thereof, wherein the polynucleotide comprises a sequence encoding a polypeptide sequence as shown in SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or a fragment thereof.

[0349] The polynucleotide encoding the idiotype-specific polypeptide of the present invention can be expressed as a single polynucleotide encoding the entire idiotype-specific polypeptide, or as a plurality of (e.g., two or more) polynucleotides of co-expression. The polypeptide encoded by the co-expressed polynucleotide can be associated by, for example, a disulfide bond or other means to form a functional idiotype-specific polypeptide, for example, a masking portion. For example, in one embodiment, the idiotype-specific polypeptide is an anti-idiotype scFv (single-chain variable fragment), wherein the light chain variable portion of the anti-idiotype scFv can be encoded by a polynucleotide separated from the portion of the anti-idiotype scFv comprising the heavy chain variable portion of the anti-idiotype scFv. When co-expressed, the heavy chain polypeptide will associate with the light chain polypeptide to form an anti-idiotype scFv. In some embodiments, the isolated polynucleotide encodes an idiotype-specific polypeptide according to the present invention as described herein.

[0350] In certain embodiments, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the invention is RNA, for example in the form of messenger RNA (mRNA). The RNA of the invention can be single-stranded or double-stranded.

[0351] Recombination methods

[0352] The protease-activatable T cell activation bispecific molecules of the present invention can be obtained, for example, by solid-state peptide synthesis (e.g., Merrifield solid phase synthesis) or recombinant production. For recombinant production, one or more polynucleotides encoding protease-activatable T cell activation bispecific molecules (fragments) as described above are separated and inserted into one or more vectors for further cloning and / or expression in host cells. Such polynucleotides can be easily separated and sequenced using conventional methods. In one embodiment, a vector is provided, preferably an expression vector, which contains one or more polynucleotides in the polynucleotides of the present invention. Methods well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of protease-activatable T cell activation bispecific molecules (fragments) and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, synthetic technology, and in vivo recombination / genetic recombination. See, for example, the techniques described in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY (1989). The expression vector may be part of a plasmid, a virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which a polynucleotide encoding a protease-activatable T cell activation bispecific molecule (fragment) operably associated with a promoter and / or other transcriptional or translational control elements (i.e., a coding region) is cloned. As used herein, a "coding region" is a portion of a nucleic acid that consists of codons that are translated into amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not translated into amino acids, it (if present) may be considered to be part of the coding region, while any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, 5' and 3' untranslated regions, etc. are not part of the coding region. Two or more coding regions may be present in a single polynucleotide construct (e.g., on a single vector), or in separate polynucleotide constructs (e.g., on separate (different) vectors). In addition, any vector may contain a single coding region, or may comprise two or more coding regions, for example, a vector of the invention may encode one or more polypeptides that are separated into final proteins by proteolytic cleavage after or during translation.In addition, the vectors, polynucleotides or nucleic acids of the present invention may encode heterologous coding regions that are fused or unfused to a polynucleotide encoding a protease-activatable T cell activation bispecific molecule (fragment) of the present invention or a variant or derivative thereof. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains. Operable association is when the coding region of a gene product (e.g., a polypeptide) is associated with one or more regulatory sequences in a manner such that the expression of the gene product is under the influence or control of the regulatory sequences. If the induction of promoter function results in the transcription of mRNA encoding the desired gene product, and if the nature of the bond between the two DNA fragments does not interfere with the ability of the expression regulatory sequence to direct the expression of the gene product or the ability of the DNA template to be transcribed, then the two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated". Thus, if the promoter is able to affect the transcription of the nucleic acid, the promoter region will be operably associated with the nucleic acid encoding the polypeptide. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in a predetermined cell. In addition to the promoter, other transcription control elements, such as enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. Such regions include, but are not limited to, transcription control regions that function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegalovirus (e.g., the immediate early promoter, along with intron A), simian virus 40 (e.g., the early promoter), and retroviruses (such as Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes (such as actin, heat shock protein, bovine growth hormone, and rabbit). The expression cassette may also include other features, such as an origin of replication, and / or a chromosomal integration element, such as a retroviral long terminal repeat (LTR), or an adeno-associated virus (AAV) inverted terminal repeat (ITR).

[0353] The polynucleotides and nucleic acid coding regions of the present invention may be associated with additional coding regions encoding secretory peptides or signal peptides that direct the secretion of the polypeptides encoded by the polynucleotides of the present invention. For example, if it is desired to secrete a protease-activatable T cell activation bispecific molecule, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding the protease-activatable T cell activation bispecific molecule of the present invention or a fragment thereof. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein once the growing protein chain has been initiated to export across the rough endoplasmic reticulum. Those of ordinary skill in the art know that polypeptides secreted by vertebrate cells typically have a signal peptide fused to the N-terminus of the polypeptide that is cleaved from the translated polypeptide to produce a secreted or "mature" form of the polypeptide. In certain embodiments, a natural signal peptide (e.g., an immunoglobulin heavy chain or light chain signal peptide) is used, or a functional derivative of the sequence that retains the ability to direct the secretion of a polypeptide operably associated therewith. Alternatively, a heterologous mammalian signal peptide or a functional derivative thereof may be used. For example, the wild-type leader sequence can be replaced by the leader sequence of human tissue plasminogen activator (TPA) or mouse beta-glucuronidase.

[0354] DNA encoding a short protein sequence that can be used to facilitate later purification (e.g., a histidine tag) or to aid in labeling the protease-activatable T cell activating bispecific molecule can be included within or at the end of the protease-activatable T cell activating bispecific molecule (fragment) encoding the polynucleotide.

[0355] In another embodiment, a host cell comprising one or more polynucleotides of the present invention is provided. In certain embodiments, a host cell comprising one or more vectors of the present invention is provided. Polynucleotides and vectors may be infiltrated individually or in combination with any of the features described herein for polynucleotides and vectors, respectively. In one such embodiment, the host cell comprises a vector (e.g., a vector has been transformed or transfected), the vector comprising a polynucleotide encoding a protease-activatable T cell activation bispecific molecule (part thereof) of the present invention. As used herein, the term "host cell" refers to any type of cell system that can be engineered to produce a protease-activatable T cell activation bispecific molecule of the present invention or a fragment thereof. Host cells suitable for replication and expression of protease-activatable T cell activation bispecific molecules are well known in the art. Such cells can be transfected or transduced with specific expression vectors, and a large number of cells containing the vector can be grown for inoculation of large fermentation tanks to obtain sufficient protease-activatable T cell activation bispecific molecules for clinical applications. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, etc. For example, polypeptides can be produced in bacteria, particularly when glycosylation is not required. The polypeptides can be separated from bacterial cell paste in a soluble fraction after expression, and can be further purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding polypeptides, including fungi and yeast strains whose glycosylation pathways have been "humanized", thereby resulting in the production of polypeptides with partial or complete human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004) and Li et al., Nat Biotech 24, 210-215 (2006). Suitable host cells for expressing (glycosylated) polypeptides also come from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Many baculovirus strains that can be used with insect cells have been identified, particularly for transfecting Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TMTechniques). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells, as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (TM4 cells, as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals NY Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr - CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines, such as YO, NS0, P3X63 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, such as mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, etc., and also include cells contained in transgenic animals, transgenic plants or cultured plants or animal tissues. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphocyte (e.g., Y0, NS0, Sp20 cell).

[0356] Standard techniques for expressing foreign genes in these systems are known in the art. Cells expressing polypeptides comprising antigen binding domains, such as heavy or light chains of antibodies, can be engineered to also express another antibody chain so that the expressed product is an antibody having heavy and light chains.

[0357] In one embodiment, a method for producing a protease-activatable T cell activating bispecific molecule according to the present invention is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding a protease-activatable T cell activating bispecific molecule as provided herein under conditions suitable for expressing the protease-activatable T cell activating bispecific molecule, and recovering the protease-activatable T cell activating bispecific molecule from the host cell (or host cell culture medium).

[0358] The components of the protease-activatable T cell activation bispecific molecule are genetically fused to each other. The protease-activatable T cell activation bispecific molecule can be designed so that its components are directly fused to each other or indirectly fused through a linker sequence. The composition and length of the linker can be measured according to methods well known in the art, and the efficacy of the linker can be tested. Examples of linker sequences between the different components of the protease-activatable T cell activation bispecific molecule are found in the sequences provided herein. If necessary, additional sequences (e.g., endopeptidase recognition sequences) may also be included to separate the individual components of the fusion by incorporating a cleavage site.

[0359] In certain embodiments, one or more antigen binding portions of the protease-activatable T cell bispecific molecules of the present invention at least comprise an antibody variable region capable of binding an antigenic determinant. The variable region can form a part of and be derived from a natural or non-naturally occurring antibody and its fragment. Methods for producing polyclonal antibodies and monoclonal antibodies are well known in the art (see, e.g., Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be recombinantly produced (e.g., as described in U.S. Patent No. 4,186,567), or can be obtained, for example, by screening a combinatorial library comprising a variable heavy chain and a variable light chain (see, e.g., U.S. Patent No. 5,969,108 of McCafferty).

[0360] Antibodies, antibody fragments, antigen binding domains or variable regions of any animal species can be used in the protease-activatable T cell activation bispecific molecules of the present invention. Non-limiting antibodies, antibody fragments, antigen binding domains or variable regions that can be used in the present invention can be of mouse, primate or human origin. If the protease-activatable T cell activation bispecific molecule is intended for human use, a chimeric form of the antibody can be used, wherein the constant region of the antibody is from a human. Humanized or fully human forms of antibodies can also be prepared according to methods well known in the art (see, for example, U.S. Patent No. 5,565,332 to Winter). Humanization can be achieved by various methods, including but not limited to (a) grafting non-human (e.g., donor antibody) CDRs onto human (e.g., acceptor antibody) frameworks and constant regions with or without retaining key framework residues (e.g., key framework residues important for maintaining good antigen binding affinity or antibody function), (b) grafting only non-human specificity determining regions (SDRs or a-CDRs; residues that are critical for antibody-antigen interactions) onto human frameworks and constant regions, or (c) grafting entire non-human variable domains but "hiding" them with human-like segments by replacing surface residues.Humanized antibodies and methods for their preparation are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and further described, e.g., in Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR(a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing the "guided selection" method for FR shuffling). Various techniques known in the art can be used to produce human antibodies and human variable regions. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form a part of a human monoclonal antibody prepared by a hybridoma method and be derived from the antibody (see, e.g., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).Human antibodies and human variable regions can also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions that respond to antigenic challenge (see, e.g., Lonberg, Nat Biotech 23, 1117-1125 (2005)). Human antibodies and human variable regions can also be produced by isolating Fv clone variable region sequences selected from phage display libraries of human origin (see, e.g., Hoogenboom et al. Methods in Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phages typically display antibody fragments as single-chain Fv (scFv) fragments or Fab fragments.

[0361] In certain embodiments, antigen binding moieties useful in the present invention are engineered to have enhanced binding affinity according to the methods disclosed, for example, in U.S. Patent Application Publication No. 2004 / 0132066, which is incorporated herein by reference in its entirety. The ability of the protease-activatable T cell activating bispecific molecules of the invention to bind to specific antigenic determinants can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art (e.g., surface plasmon resonance (analyzed on a BIACORE T100 system) (Liljeblad, et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition assays can be used to identify antibodies, antibody fragments, antigen binding domains or variable domains that compete with a reference antibody for binding to a particular antigen, such as antibodies that compete with the V9 antibody for binding to CD3. In certain embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) as that bound by the reference antibody. Detailed exemplary methods for mapping epitopes bound by antibodies are provided in Morris (1996) "Epitope Mapping in Methods in Molecular Biology Vol. 66 (Humana Press, Totowa, NJ). In an exemplary competition assay, an immobilized antigen (e.g., CD3) is incubated in a solution comprising a first labeled antibody (e.g., the V9 antibody described in U.S. Pat. No. 6,054,297) that binds to the antigen and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to the antigen. The second antibody may be present in the hybridoma supernatant. As a control, the immobilized antigen is incubated in a solution comprising the first labeled antibody rather than the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to the antigen, excess unbound antibody is removed and the amount of label associated with the immobilized antigen is measured. If the amount of label associated with the immobilized antigen in the test sample is significantly reduced relative to the control sample, it indicates that the second antibody is competing with the first antibody for binding to the antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual Chapter 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0362] The protease-activatable T cell activation bispecific molecules prepared as described herein can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions for purifying a particular protein will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and will be apparent to those skilled in the art. For affinity chromatography purification, antibodies, ligands, receptors or antigens that bind to the protease-activatable T cell activation bispecific molecules can be used. For example, for affinity chromatography purification of the protease-activatable T cell activation bispecific molecules of the present invention, a matrix with protein A or protein G can be used. Basically as described in the examples, sequence protein A or G affinity chromatography and size exclusion chromatography can be used to separate the protease-activatable T cell activation bispecific molecules. The purity of the protease-activatable T cell activation bispecific molecules can be determined by any of a variety of well-known analytical methods, including gel electrophoresis, high pressure liquid chromatography, etc. For example, the heavy chain fusion protein expressed as described in the Examples was shown to be intact and correctly assembled, as demonstrated by reducing SDS-PAGE (see, e.g., Figures 8 to 12). Three bands were resolved at approximately Mr 25,000, Mr 50,000, and Mr 75,000, corresponding to the predicted molecular weights of the protease-activatable T cell activating bispecific molecule light chain, heavy chain, and heavy chain / light chain fusion protein.

[0363] Determination

[0364] The protease-activatable T cell activating bispecific molecules provided herein can be identified, screened or characterized for their physical / chemical properties and / or biological activity by various assays known in the art.

[0365] Affinity determination

[0366] The affinity of protease-activatable T cell activation bispecific molecules to Fc receptors or target antigens can be determined by surface plasmon resonance (SPR) using standard instruments such as BIAcore instruments (GE Healthcare) and receptors or target proteins such as those obtainable by recombinant expression according to the methods set forth in the examples. Alternatively, the binding of protease-activatable T cell activation bispecific molecules to different receptors or target antigens can be assessed using cell lines expressing specific receptors or target antigens, such as by flow cytometry (FACS). Specific illustrative and exemplary embodiments for measuring binding affinity are described below and in the following examples.

[0367] According to one embodiment, the K was measured by surface plasmon resonance using a T100 instrument (GE Healthcare).D .

[0368] To analyze the interaction between the Fc part and the Fc receptor, His-tagged recombinant Fc receptors were captured by anti-pentahistidine antibodies (Qiagen) immobilized on a CM5 chip, and the bispecific constructs were used as analytes. Briefly, carboxymethylated dextran biosensor chips (CM5, GE Healthcare) were activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. The anti-pentahistidine antibody was diluted to 40 μg / ml with 10 mM sodium acetate pH 5.0 and then injected at a flow rate of 5 μl / min to obtain approximately 6500 response units (RU) of coupled protein. After the ligand was injected, 1 M ethanolamine was injected to block unreacted groups. The Fc receptor was then captured at 4 or 10 nM for 60 s. For kinetic measurements, four-fold serial dilutions of the bispecific constructs (ranging between 500 nM and 4000 nM) were injected into HBS-EP (GE Healthcare, 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, pH 7.4) at 25°C at a flow rate of 30 μl / min for 120 sec.

[0369] To determine the affinity to the target antigen, the bispecific construct was captured by an anti-human Fab specific antibody (GE Healthcare) immobilized on the surface of an activated CM5 sensor chip, as described for the anti-pentahistidine antibody. The final amount of coupled protein was approximately 12000RU. The bispecific construct was captured at 300nM for 90s. The target antigen was passed through the flow cell at a concentration range of 250 to 1000nM at a flow rate of 30μl / min for 180s. Dissociation was monitored for 180s.

[0370] Bulk refractive index differences were corrected by subtracting the response obtained in a reference flow cell. The steady-state response was used to derive the dissociation constant, K, by nonlinear curve fitting of the Langmuir binding isotherm. D Using a simple one-to-one Langmuir binding model ( T100 Evaluation Software version 1.1.1) and the association rate (k) was calculated by simultaneously fitting the association and dissociation sensorgrams. on ) and dissociation rate (k off ). Equilibrium dissociation constant (K D ) is calculated as the ratio k off / k on See, e.g., Chen et al., J Mol Biol 293, 865-881 (1999).

[0371] Activity assay

[0372] The biological activity of the protease-activatable T cell activation bispecific molecules of the present invention can be measured by various assays as described in the examples. Biological activity can, for example, include induction of T cell proliferation, induction of signal transduction in T cells, induction of activation marker expression in T cells, induction of T cell cytokine secretion, induction of target cell (e.g., tumor cell) lysis, and induction of tumor regression and / or improved survival.

[0373] Composition, formulation and route of administration

[0374] In a further aspect, the invention provides a pharmaceutical composition comprising any of the protease-activatable T cell activation bispecific molecules provided herein, which is used, for example, in any of the following treatment methods. In one embodiment, the pharmaceutical composition comprises any of the protease-activatable T cell activation bispecific molecules provided herein, and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical composition comprises any of the protease-activatable T cell activation bispecific molecules provided herein, and at least one additional therapeutic agent, such as described below.

[0375] Further provided is a method for producing a protease-activatable T cell activating bispecific molecule of the present invention in a form suitable for in vivo administration, the method comprising (a) obtaining a protease-activatable T cell activating bispecific molecule according to the present invention, and (b) formulating the protease-activatable T cell activating bispecific molecule with at least one pharmaceutically acceptable carrier, wherein the preparation of the protease-activatable T cell activating bispecific molecule is formulated for in vivo administration.

[0376] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more protease-activatable T cell activating bispecific molecules dissolved or dispersed in a pharmaceutical carrier. The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that are generally non-toxic to recipients at the doses and concentrations employed, i.e., do not produce adverse, allergic or other adverse reactions when administered to animals (such as, for example, humans) as appropriate. The preparation of pharmaceutical compositions containing at least one protease-activatable T cell activating bispecific molecule and optional additional active ingredients will be known to those skilled in the art in view of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th edition, Mack Printing Company, 1990, which is incorporated herein by reference. In addition, for animal (e.g., human) administration, it should be understood that the preparation should meet the sterility, pyrogenicity, general safety and purity standards required by the FDA Office of Biological Standards or other national / regional authorities. The preferred composition is a lyophilized formulation or an aqueous solution. As used herein, "pharmaceutical carrier" includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, such and similar substances and combinations thereof, as would be known to one of ordinary skill in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th Edition, Mack Printing Company, 1990, pp. 1289-1329, which is incorporated herein by reference). Except in the case where any conventional carrier is incompatible with the active ingredient, the use of such carrier in the therapeutic or pharmaceutical composition is contemplated.

[0377] The composition may contain different types of carriers, depending on whether it is administered in solid, liquid or aerosol form, and whether it needs to be sterile for routes of administration such as injection. The protease-activatable T cell activating bispecific molecules of the invention (and any additional therapeutic agent) may be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrasplenicly, intrarenally, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intracapsularly, intramucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, topically, by inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, local perfusion directly to bathe target cells, via catheter, via lavage, in cream form, in lipid composition (e.g., liposomes), or by other methods known to those of ordinary skill in the art or any combination of the foregoing (see, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Printing Company, 1990, which is incorporated herein by reference). Parenteral administration, particularly intravenous injection, is most commonly used to administer polypeptide molecules, such as the protease-activatable T cell activating bispecific molecules of the invention.

[0378] Parenteral compositions include those designed for administration by injection (e.g., subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal or intraperitoneal injection). For injection, the protease-activatable T cell activation bispecific molecules of the present invention can be formulated in an aqueous solution, preferably in a physiologically compatible buffer (such as Hanks solution, Ringer's solution or saline buffer). The solution may contain a formulation agent (formulatoryagent), such as a suspending agent, a stabilizer and / or a dispersant. Alternatively, the protease-activatable T cell activation bispecific molecule can be in powder form for use in a suitable solvent (e.g., sterile pyrogen-free water) before use. Sterile injectable solutions are prepared by incorporating the protease-activatable T cell activation bispecific molecules of the present invention in the desired amount together with the various other ingredients listed below into an appropriate solvent as needed. For example, sterility can be easily achieved by filtering through a sterile filtration membrane. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile solvent containing a basic dispersion medium and / or other components. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsions, preferred preparation methods are vacuum drying or freeze drying techniques, which produce a powder of the active ingredient from a previously sterile filtered liquid medium plus any additional required ingredients. If necessary, the liquid medium should be properly buffered, and sufficient saline or glucose should first be used to make the liquid diluent isotonic before injection. The composition must be stable under manufacturing and storage conditions, and is preserved as a contamination effect against microorganisms such as bacteria and fungi. It should be understood that endotoxin contamination should be kept to a minimum, for example, at a safety level below 0.5 ng / mg protein. Suitable pharmaceutical carriers include, but are not limited to, buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as Serum albumin, gelatin or immunoglobulin; hydrophilic polymers such as polyvinyl pyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zinc protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, dextran, etc.Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a highly concentrated solution. In addition, the suspension of the active compound may be prepared as an appropriate oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil; or synthetic fatty acid esters such as ethyl oleate or triglycerides; or liposomes.

[0379] The active ingredient can be embedded in microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared, for example, by coacervation techniques or by interfacial polymerization; embedded in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules); or embedded in coarse emulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th edition, Mack Printing Company, 1990). Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing polypeptides in the form of molded articles such as films or microcapsules. In particular embodiments, extended absorption of injectable compositions can be achieved by using agents that delay absorption in the composition (such as, for example, aluminum monostearate, gelatin, or a combination thereof).

[0380] In addition to the compositions described previously, the protease-activatable T cell activation bispecific molecules can also be formulated into long-acting preparations. Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular implantation) or by intramuscular injection. Therefore, for example, the protease-activatable T cell activation bispecific molecules can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or with ion exchange resins, or formulated as slightly soluble derivatives, such as formulated as slightly soluble salts.

[0381] Pharmaceutical compositions comprising the protease-activatable T cell activating bispecific molecules of the invention can be manufactured by conventional mixing, dissolving, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions can be formulated in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or adjuvants that aid in processing the protein into pharmaceutically usable preparations. Appropriate formulations depend on the selected route of administration.

[0382] Protease-activatable T cell activating bispecific molecules can be formulated as compositions in free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or free base. These pharmaceutically acceptable salts include acid addition salts, such as acid addition salts formed with free amino groups of protein compositions, or acid addition salts formed with inorganic acids (such as hydrochloric acid or phosphoric acid) or organic acids (such as acetic acid, oxalic acid, tartaric acid or mandelic acid). Salts formed with free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ferric hydroxide; or organic bases such as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutically acceptable salts tend to be more soluble in aqueous and other protic solvents than the corresponding free base forms.

[0383] Methods of treatment and compositions

[0384] Any of the protease-activatable T cell activating bispecific molecules provided herein can be used in therapeutic methods.The protease-activatable T cell activating bispecific molecules of the invention can be used as immunotherapeutic agents, for example, for the treatment of cancer.

[0385] For use in therapeutic methods, the protease-activatable T cell activating bispecific molecules of the invention will be formulated, dosed and administered in a manner consistent with good medical practice. Factors to be considered in this context include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the timing of administration, and other factors known to practitioners.

[0386] In one aspect, a protease-activatable T cell activation bispecific molecule of the present invention for use as a medicament is provided. In a further aspect, a protease-activatable T cell activation bispecific molecule of the present invention for treating a disease is provided. In certain embodiments, a protease-activatable T cell activation bispecific molecule of the present invention for use in a method of treatment is provided. In one embodiment, the present invention provides a protease-activatable T cell activation bispecific molecule as described herein for treating a disease in an individual in need thereof. In certain embodiments, the present invention provides a protease-activatable T cell activation bispecific molecule for use in a method for treating an individual suffering from a disease, the method comprising administering to the individual a therapeutically effective amount of a protease-activatable T cell activation bispecific molecule. In certain embodiments, the disease to be treated is a proliferative disorder. In a specific embodiment, the disease is cancer. In certain embodiments, the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, for example, if the disease to be treated is cancer, an anticancer agent is used. In a further embodiment, the present invention provides a protease-activatable T cell activation bispecific molecule as described herein for inducing lysis of target cells, particularly tumor cells. In certain embodiments, the present invention provides a protease-activatable T cell activating bispecific molecule for use in a method of inducing lysis of target cells, particularly tumor cells, in an individual, the method comprising administering to the individual an effective amount of the protease-activatable T cell activating bispecific molecule to induce lysis of the target cells. According to any of the above embodiments, the "individual" is a mammal, preferably a human.

[0387] In a further aspect, the present invention provides the use of the protease-activatable T cell activating bispecific molecule of the present invention in the manufacture or preparation of a drug. In one embodiment, the drug is used to treat a disease in an individual in need thereof. In another embodiment, the drug is used in a method for treating a disease, the method comprising administering a therapeutically effective amount of the drug to an individual having the disease. In certain embodiments, the disease to be treated is a proliferative disorder. In a specific embodiment, the disease is cancer. In one embodiment, the method further comprises administering a therapeutically effective amount of at least one additional therapeutic agent to the individual, for example, if the disease to be treated is cancer, an anticancer agent is used. In a further embodiment, the drug is used to induce lysis of target cells, particularly tumor cells. In yet another embodiment, the drug is used in a method for inducing lysis of target cells, particularly tumor cells, in an individual, comprising administering an effective amount of the drug to the individual to induce lysis of the target cells. The "individual" according to any of the above embodiments may be a mammal, preferably a human.

[0388] In a further aspect, the present invention provides a method for treating a disease. In one embodiment, the method comprises administering a therapeutically effective amount of a protease-activatable T cell-activating bispecific molecule of the present invention to an individual suffering from such a disease. In one embodiment, a composition is administered to the individual, the composition comprising a protease-activatable T cell-activating bispecific molecule of the present invention in a pharmaceutical form. In certain embodiments, the disease to be treated is a proliferative disorder. In a specific embodiment, the disease is cancer. In certain embodiments, the method further comprises administering a therapeutically effective amount of at least one additional therapeutic agent to the individual, for example, if the disease to be treated is cancer, an anticancer agent is used. The "individual" according to any of the above embodiments can be a mammal, preferably a human.

[0389] On the other hand, the present invention provides a method for inducing the lysis of target cells, particularly tumor cells. In one embodiment, the method includes contacting the target cells with the protease-activatable T cell activating bispecific molecule of the present invention in the presence of T cells, particularly cytotoxic T cells. On the other hand, a method for inducing the lysis of target cells, particularly tumor cells, in an individual is provided. In one such embodiment, the method includes administering to the individual an effective amount of a protease-activatable T cell activating bispecific molecule to induce the lysis of the target cells. In one embodiment, the individual is a human.

[0390] In certain embodiments, the disease to be treated is a proliferative disorder, particularly cancer. Non-limiting examples of cancer include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and renal cancer. Other cell proliferation disorders that can be treated using the protease-activatable T cell-activating bispecific molecules of the present invention include, but are not limited to, tumors located in the following parts: abdomen, bones, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal glands, parathyroid glands, pituitary glands, testicles, ovaries, thymus, thyroid gland), eyes, head and neck, nervous system (central and peripheral nervous system), lymphatic system, pelvis, skin, soft tissue, spleen, chest, and urogenital system. Precancerous conditions or lesions and cancer metastasis are also included. In certain embodiments, the cancer is selected from the group consisting of: renal cell carcinoma, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. The skilled person will readily recognize that in many cases, the protease-activatable T cell activation bispecific molecule may not provide a cure, but may only provide a partial benefit. In some embodiments, physiological changes with some benefits are also considered to be therapeutically beneficial. Therefore, in some embodiments, the amount of the protease-activatable T cell activation bispecific molecule that provides physiological changes is considered to be an "effective amount" or a "therapeutically effective amount". The subject, patient or individual in need of treatment is typically a mammal, more particularly a human.

[0391] In some embodiments, an effective amount of a protease-activatable T cell activating bispecific molecule of the invention is administered to a cell. In other embodiments, a therapeutically effective amount of a protease-activatable T cell activating bispecific molecule of the invention is administered to an individual to treat a disease.

[0392] For the prevention or treatment of disease, the appropriate dosage of the protease-activatable T cell-activating bispecific molecule of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the patient's weight, the type of T cell-activating bispecific antigen binding molecule, the severity and progression of the disease, whether the T cell-activating bispecific antigen binding molecule is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and response to the protease-activatable T cell-activating bispecific molecule, and the discretion of the attending physician. In any case, the practitioner responsible for administration will determine the concentration and appropriate dosage of the active ingredient in the composition for individual subjects. Various dosing schedules are contemplated herein, including but not limited to single or multiple administrations, bolus administrations, and pulse infusions at various time points.

[0393] The protease-activatable T cell activation bispecific molecule is appropriately administered to the patient once or in a series of treatments. Depending on the type and severity of the disease, the protease-activatable T cell activation bispecific molecule of about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 10 mg / kg) can be, for example, an initial candidate dose administered to the patient by one or more separate administrations or by continuous infusion. Depending on the above factors, a typical daily dose may range from about 1 μg / kg to 100 mg / kg or more. For repeated administration for several days or longer, depending on the condition, treatment will generally continue until the desired disease symptom suppression occurs. An exemplary dosage of a T cell activation bispecific antigen binding molecule ranges from about 0.005 mg / kg to about 10 mg / kg. In other non-limiting examples, dosage can also include about 1 μg / kg body weight, about 5 μg / kg body weight, about 10 μg / kg body weight, about 50 μg / kg body weight, about 100 μg / kg body weight, about 200 μg / kg body weight, about 350 μg / kg body weight, about 500 μg / kg body weight, about 1 mg / kg body weight, about 5 mg / kg body weight, about 10 mg / kg body weight, about 50 mg / kg body weight, about 100 mg / kg body weight, about 200 mg / kg body weight, about 350 mg / kg body weight, about 500 mg / kg body weight, to about 1000 mg / kg body weight or more, and any range derived therefrom. In non-limiting examples of ranges derivable from the numbers listed herein, the range of about 5 mg / kg body weight to about 100 mg / kg body weight, about 5 μg / kg body weight to about 500 mg / kg body weight, etc. can be administered based on the above numerical values. Therefore, one or more dosages of about 0.5 mg / kg, 2.0 mg / kg, 5.0 mg / kg or 10 mg / kg (or any combination thereof) can be administered to the patient. Such dosages can be administered intermittently, such as weekly or every three weeks (e.g., so that the patient receives about two to about twenty or, for example, about six dosages of protease-activatable T cell activation bispecific molecules). An initial higher loading dose can be administered, followed by one or more lower doses. However, other dosage regimens may be useful. The progress of the therapy can be easily monitored by conventional techniques and determinations.

[0394] The protease-activatable T cell activating bispecific molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use in treating or preventing a condition, the protease-activatable T cell activating bispecific molecules of the invention or their pharmaceutical compositions are administered or applied in a therapeutically effective amount. The determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, particularly in light of the detailed disclosure provided herein.

[0395] For systemic administration, the therapeutically effective dose can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve an IC including that determined in cell culture. 50 Circulating concentration ranges. Such information can be used to more accurately determine useful doses in humans.

[0396] Initial doses can also be estimated based on in vivo data (eg, animal models) using techniques well known in the art. One of ordinary skill in the art can easily optimize administration to humans based on animal data.

[0397] Dosage and interval can be adjusted individually to provide plasma levels of the protease-activatable T cell activating bispecific molecule sufficient to maintain therapeutic efficacy. The range of common patient doses administered by injection is about 0.1 to 50 mg / kg / day, typically about 0.5 to 1 mg / kg / day. Therapeutically effective plasma levels can be achieved by administering multiple doses per day. Levels in plasma can be measured, for example, by HPLC.

[0398] In cases of local administration or selective uptake, the effective local concentration of the protease-activatable T cell activating bispecific molecule may not be related to plasma concentration. One skilled in the art will be able to optimize a therapeutically effective local dose without undue experimentation.

[0399] The therapeutically effective dose of the protease-activatable T cell activating bispecific molecules described herein will generally provide therapeutic benefit without causing substantial toxicity. The toxicity and therapeutic efficacy of the protease-activatable T cell activating bispecific molecules can be determined by standard pharmaceutical methods in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine the LD 50 (the dose that causes 50% of the population to die) and ED 50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 / ED 50 Protease-activatable T cell activating bispecific molecules that exhibit large therapeutic indices are preferred. In one embodiment, the protease-activatable T cell activating bispecific molecules according to the present invention exhibit a high therapeutic index. Data obtained from cell culture assays and animal studies can be used to formulate a range of doses suitable for use in humans. Doses are preferably within a range that includes ED with little or no toxicity. 50The dosage may vary within this range depending on a variety of factors, such as the dosage form employed, the route of administration utilized, the condition of the subject, etc. The exact formulation, route of administration, and dosage may be selected by an individual physician based on the patient's condition (see, e.g., Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Chapter 1, page 1, the entire contents of which are incorporated herein by reference).

[0400] The attending physician of a patient treated with the protease-activatable T cell activating bispecific molecule of the present invention should know how and when to terminate, interrupt or adjust administration due to toxicity, organ dysfunction, etc. Conversely, if the clinical response is insufficient (excluding toxicity), the attending physician will also know to adjust the treatment to a higher level. The size of the dosage used in the management of the target disorder will vary with the severity of the condition to be treated, the route of administration, etc. For example, the severity of the condition can be assessed in part by standard prognostic assessment methods. In addition, the dosage and possible dosage frequency will also vary according to the age, weight and response of the individual patient.

[0401] Other medicines and treatments

[0402] The protease-activatable T cell activation bispecific molecules according to the present invention can be administered in combination with one or more other agents in the therapy. For example, the protease-activatable T cell activation bispecific molecules of the present invention can be co-administered with at least one additional therapeutic agent. The term "therapeutic agent" includes any agent that is administered to treat the symptoms or diseases of an individual who needs such treatment. Such additional therapeutic agents may include any active ingredients suitable for the specific indications treated, preferably active ingredients with complementary activities that do not adversely affect each other. In certain embodiments, the additional therapeutic agent is an immunomodulator, a cell growth inhibitor, a cell adhesion inhibitor, a cytotoxic agent, an apoptosis activator, or an agent that increases the sensitivity of cells to apoptosis inducing agents. In a specific embodiment, the additional therapeutic agent is an anticancer agent, such as a microtubule disruptor, an antimetabolite, a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormone therapy, a kinase inhibitor, a receptor antagonist, a tumor cell apoptosis activator, or an anti-angiogenic agent.

[0403] Such other agents are appropriately present in combination in an amount effective for the intended purpose. The effective amount of such other agents depends on the amount of the protease-activatable T cell activating bispecific molecule used, the type of disorder or treatment, and other factors discussed above. The protease-activatable T cell activating bispecific molecule is generally used in the same dosage and administration route as described herein, or in about 1% to 99% of the dosage described herein, or in any dosage and any route determined empirically / clinically to be appropriate.

[0404] Such combination therapies noted above encompass both co-administration (where two or more therapeutic agents are included in the same or different compositions) and separate administration, in which case the administration of the protease-activatable T cell activating bispecific molecules of the invention may be performed before, simultaneously with, and / or after the administration of the additional therapeutic agent and / or adjuvant. The protease-activatable T cell activating bispecific molecules of the invention may also be used in combination with radiotherapy.

[0405] Products

[0406] In another aspect of the present invention, a product is provided, which contains a substance that can be used to treat, prevent and / or diagnose the above-mentioned diseases. The product includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous (IV) solution bags, etc. The container can be formed of a variety of materials such as glass or plastic. The container holds a composition that can be effectively used to treat, prevent and / or diagnose the disease itself or in combination with another composition, and the container can have a sterile access port (for example, the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle). At least one active agent in the composition is a protease-activatable T cell activation bispecific molecule of the present invention. The label or package insert indicates that the composition is used to treat the selected disease. In addition, the product may include (a) a first container containing a composition, wherein the composition comprises a protease-activatable T cell activation bispecific molecule of the present invention; and (b) a second container containing a composition, wherein the composition comprises an additional cytotoxic agent or other therapeutic agent. The article of manufacture in this embodiment of the invention may further include a package insert indicating that these compositions can be used to treat a particular condition. Alternatively or additionally, the article of manufacture may further include a second (or third) container comprising a pharmaceutical buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution, and dextrose solution. The article of manufacture may further include other substances required from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0407] Exemplary Embodiments

[0408] 1. A protease-activatable T cell-activating bispecific molecule comprising

[0409] (a) a first antigen binding portion capable of binding to CD3;

[0410] (b) a second antigen binding moiety capable of binding to a target cell antigen; and

[0411] (c) a masking moiety covalently linked to the T cell bispecific binding molecule via a peptide linker, wherein the masking moiety is capable of binding to the idiotype of the first antigen binding moiety or the second antigen binding moiety, thereby reversibly concealing the first antigen binding moiety or the second antigen binding moiety,

[0412] The linker comprises a protease recognition sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

[0413] 2. The protease-activatable T cell activating bispecific molecule according to Example 1, wherein the masking moiety is covalently attached to the first antigen binding moiety and reversibly conceals the first antigen binding moiety.

[0414] 3. The protease-activatable T cell activating bispecific molecule according to embodiment 1 or 2, wherein the masking moiety is covalently linked to the heavy chain variable region of the first antigen binding moiety.

[0415] 4. The protease-activatable T cell activating bispecific molecule according to embodiment 1 or 2, wherein the masking moiety is covalently linked to the light chain variable region of the first antigen binding moiety.

[0416] 5. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 4, wherein the masking moiety is a scFv.

[0417] 6. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 5, wherein the protease-activatable T cell activating bispecific molecule comprises a second masking portion that reversibly conceals the second antigen binding portion.

[0418] 7. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 6, wherein the protease is expressed by a target cell.

[0419] 8. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 7, wherein (i) the second antigen binding portion is a conventional Fab, or (ii) the second antigen binding portion is a crossover Fab molecule in which the variable regions or constant regions of the Fab light chain and the Fab heavy chain are exchanged.

[0420] 9. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 8, wherein the second antigen binding moiety is a crossover Fab molecule, wherein the Fab light chain is exchanged with the Fab heavy chain constant region.

[0421] 10. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 9, wherein the first antigen binding moiety is a conventional Fab molecule.

[0422] 11. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 10, comprising no more than one antigen binding portion capable of binding to CD3.

[0423] 12. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 11, comprising a third antigen binding portion, wherein the third antigen binding portion is a Fab molecule capable of binding to a target cell antigen.

[0424] 13. The protease-activatable T cell activating bispecific molecule of embodiment 12, wherein the third antigen binding moiety is the same as the second antigen binding moiety.

[0425] 14. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 13, wherein the second antigen binding moiety is capable of binding to FolR1.

[0426] 15. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 14, wherein the first antigen binding moiety and the second antigen binding moiety are fused to each other, optionally via a peptide linker.

[0427] 16. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 15, wherein the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain.

[0428] 17. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 15, wherein the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety.

[0429] 18. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 17, wherein the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety are fused to each other, optionally via a peptide linker.

[0430] 19. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 18, further comprising an Fc domain composed of a first subunit and a second subunit capable of stably associating.

[0431] 20. The protease-activatable T cell activating bispecific molecule according to embodiment 19, wherein the Fc domain is an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.

[0432] 21. The protease-activatable T cell activating bispecific molecule according to embodiment 19 or 20, wherein the Fc domain is a human Fc domain.

[0433] 22. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 19 to 21, wherein the Fc domain exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain.

[0434] 23. The protease-activatable T cell activating bispecific molecule of embodiment 22, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0435] 24. The protease-activatable T cell activating bispecific molecule according to embodiment 23, wherein the one or more amino acid substitutions are at one or more positions selected from the group consisting of L234, L235 and P329 (Kabat numbering).

[0436] 25. The protease-activatable T cell activating bispecific molecule of Example 24, wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce binding to an activated Fc receptor and / or effector function, wherein the amino acid substitutions are L234A, L235A and P329G.

[0437] 26. The protease-activatable T cell activating bispecific molecule of any one of embodiments 22 to 25, wherein the Fc receptor is an Fcγ receptor.

[0438] 27. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 22 to 26, wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

[0439] 28. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27, wherein the portion capable of binding to CD3 comprises

[0440] (i) a heavy chain variable (VH) region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 1, HCDR 2 of SEQ ID NO: 2, and HCDR 3 of SEQ ID NO: 3, and

[0441] (ii) a light chain variable (VL) region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:7, LCDR 2 of SEQ ID NO:8, and LCDR 3 of SEQ ID NO:9.

[0442] 29. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 28, wherein the portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 5; and / or the VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0443] 30. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27, wherein the portion capable of binding to CD3 comprises

[0444] (i) a heavy chain variable (VH) region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 1, HCDR 2 of SEQ ID NO: 2, and HCDR 3 of SEQ ID NO: 4, and

[0445] (ii) a light chain variable (VL) region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:7, LCDR 2 of SEQ ID NO:8, and LCDR 3 of SEQ ID NO:9.

[0446] 31. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27 or 30, wherein the portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 6; and / or the VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0447] 32. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 31, wherein the masking moiety comprises a heavy chain variable region comprising at least one of:

[0448] (a) heavy chain complementarity determining region (HCDR) 1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0449] (b) a HCDR2 amino acid sequence selected from the group consisting of WINTETGEPRYTDDFKG (SEQ ID NO: 16), WINTETGEPRYTDDFTG (SEQ ID NO: 17) and WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0450] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19).

[0451] 33. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 32, wherein the masking moiety comprises a light chain variable region comprising at least one of:

[0452] (d) the light chain complementary determining region (LCDR) 1a amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25) or KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0453] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0454] (f) LCDR3 amino acid sequence selected from the group consisting of QHSREFPYT (SEQ ID NO: 28) or QQSREFPYT (SEQ ID NO: 29).

[0455] 34. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises a heavy chain variable region comprising:

[0456] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0457] (b) a HCDR2 amino acid sequence selected from the group consisting of WINTETGEPRYTDDFKG (SEQ ID NO: 16), WINTETGEPRYTDDFTG (SEQ ID NO: 17) and WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0458] (c) a HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 60); and a light chain variable region comprising:

[0459] (d) a LCDR1 amino acid sequence selected from the group consisting of RASKSVSTSSYSYMH (SEQ ID NO: 25) and KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0460] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0461] (f) a LCDR3 amino acid sequence selected from the group consisting of QHSREFPYT SEQ ID NO: 28 and QQSREFPYT (SEQ ID NO: 29).

[0462] 35. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises: a VH region comprising:

[0463] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0464] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0465] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0466] and a VL region comprising:

[0467] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0468] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0469] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0470] 36. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises: a VH region comprising:

[0471] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0472] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0473] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0474] and a VL region comprising:

[0475] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0476] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0477] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0478] 37. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises: a VH region comprising:

[0479] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0480] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFTG (SEQ ID NO: 17);

[0481] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0482] and a VL region comprising:

[0483] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0484] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0485] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0486] 38. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises: a VH region comprising:

[0487] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0488] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0489] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0490] and a VL region comprising:

[0491] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0492] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0493] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0494] 39. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking moiety comprises: a VH region comprising:

[0495] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0496] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0497] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0498] and a VL region comprising:

[0499] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0500] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0501] (f) LCDR3 amino acid sequence of QQSREFPYT (SEQ ID NO: 29).

[0502] 40. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 39, wherein the masking moiety is humanized.

[0503] 41. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 40, wherein the masking portion comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 21; and a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 32.

[0504] 42. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 33, wherein the masking portion comprises: a VH region comprising the amino acid sequence of SEQ ID NO: 21; and a VL region comprising the amino acid sequence of SEQ ID NO: 32.

[0505] 43. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 40, wherein the second antigen binding portion is capable of binding to FolR1 and comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 and / or at least one light chain CDR selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

[0506] 44. The protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 43, wherein the second antigen binding portion is capable of binding to FolR1 and comprises a heavy chain variable region comprising:

[0507] a) HCDR1 amino acid sequence of NAWMS (SEQ ID NO: 11);

[0508] b) the HCDR2 amino acid sequence of RIKSKTDGGTTDYAAPVKG (SEQ ID NO: 12); and

[0509] c) HCDR3 amino acid sequence of PWEWSWYDY (SEQ ID NO: 13);

[0510] and a VL region comprising:

[0511] d) LCDR1 of GSSTGAVTTSNYAN (SEQ ID NO:7);

[0512] e) the LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and

[0513] f) LCDR3 amino acid sequence of ALWYSNLWV (SEQ ID NO: 9).

[0514] 45. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 44, wherein the second antigen binding portion comprises: a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14, and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.

[0515] 46. ​​The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 44, wherein the second antigen binding portion is capable of binding to FolR1 and comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10.

[0516] 47. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 46, wherein the protease-cleavable linker comprises the protease recognition sequence PQARK (SEQ ID NO: 41).

[0517] 48. A protease-activatable T cell-activating bispecific molecule comprising

[0518] (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO: 46;

[0519] (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO: 48; and

[0520] (c) a light chain comprising the amino acid sequence of SEQ ID NO:45.

[0521] 49. A protease-activatable T cell-activating bispecific molecule comprising

[0522] (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO: 46;

[0523] (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO: 49; and

[0524] (c) a light chain comprising the amino acid sequence of SEQ ID NO:45.

[0525] 50. A protease-activatable T cell-activating bispecific molecule comprising

[0526] (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO: 46;

[0527] (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO: 53; and

[0528] (c) a light chain comprising the amino acid sequence of SEQ ID NO:45.

[0529] 51. A protease-activatable T cell-activating bispecific molecule comprising

[0530] (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO: 46;

[0531] (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO: 54; and

[0532] (c) a light chain comprising the amino acid sequence of SEQ ID NO:45.

[0533] 52. A protease-activatable T cell-activating bispecific molecule comprising

[0534] (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO: 46;

[0535] (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO: 55; and

[0536] (c) a light chain comprising the amino acid sequence of SEQ ID NO:45.

[0537] 53. An idiotype-specific polypeptide for reversibly concealing an anti-CD3 antigen binding site of a molecule, wherein the idiotype-specific polypeptide is covalently linked to the molecule via a peptide linker, wherein the linker comprises a protease recognition sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

[0538] 54. The idiotype-specific polypeptide of embodiment 52, wherein the idiotype-specific polypeptide is an anti-idiotype scFv, an anti-idiotype Fab, or an anti-idiotype scFab.

[0539] 55. The idiotype-specific polypeptide of embodiment 53 or 54, wherein the idiotype-specific polypeptide is a scFv.

[0540] 56. The idiotype-specific polypeptide of any one of embodiments 53 to 55, wherein said molecule is a T cell activating bispecific molecule.

[0541] 57. The idiotype-specific polypeptide of any one of embodiments 53 to 56, wherein the idiotype-specific polypeptide comprises: a heavy chain variable (VH) region comprising:

[0542] (a) the heavy chain complementarity determining region (HCDR) 1 amino acid sequence of DYSMN (SEQ ID NO: 15),

[0543] (b) a HCDR2 amino acid sequence selected from the group consisting of WINTETGEPRYTDDFKG (SEQ ID NO: 16), WINTETGEPRYTDDFTG (SEQ ID NO: 17) and WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0544] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0545] and a light chain variable (VL) region comprising:

[0546] (d) the light chain complementarity determining region (LCDR) 1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25) or KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0547] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0548] (f) LCDR3 amino acid sequences of QHSREFPYT (SEQ ID NO: 28) and QQSREFPYT (SEQ ID NO: 29).

[0549] 58. The idiotype-specific polypeptide of any one of embodiments 53 to 57, wherein said idiotype-specific polypeptide comprises: a VH region comprising:

[0550] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0551] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0552] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0553] and a VL region comprising:

[0554] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0555] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0556] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0557] 59. The idiotype-specific polypeptide of any one of embodiments 53 to 57, wherein the idiotype-specific polypeptide comprises: a VH region comprising:

[0558] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0559] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16);

[0560] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0561] and a VL region comprising:

[0562] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0563] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0564] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0565] 60. The idiotype-specific polypeptide of any one of embodiments 53 to 57, wherein said idiotype-specific polypeptide comprises: a VH region comprising:

[0566] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0567] (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFTG (SEQ ID NO: 17);

[0568] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0569] and a VL region comprising:

[0570] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0571] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0572] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0573] 61. The idiotype-specific polypeptide of any one of embodiments 53 to 57, wherein said idiotype-specific polypeptide comprises: a VH region comprising:

[0574] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0575] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0576] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0577] and a VL region comprising:

[0578] (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26);

[0579] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0580] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0581] 62. The idiotype-specific polypeptide of any one of embodiments 53 to 57, wherein said idiotype-specific polypeptide comprises: a VH region comprising:

[0582] (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15);

[0583] (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18);

[0584] (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19);

[0585] and a VL region comprising:

[0586] (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25);

[0587] (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and

[0588] (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

[0589] 63. The idiotype-specific polypeptide of any one of embodiments 53 to 62, wherein said protease-cleavable linker comprises a protease recognition sequence PQARK (SEQ ID NO: 41).

[0590] 64. The idiotype-specific polypeptide of any one of embodiments 53 to 63, wherein the idiotype-specific polypeptide comprises: a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24; and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34.

[0591] 65. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:21 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:31.

[0592] 66. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:21 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.

[0593] 67. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:22 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.

[0594] 68. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:23 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.

[0595] 69. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:23 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:29.

[0596] 70. The idiotype-specific polypeptide of any one of embodiments 53 to 64, wherein the idiotype-specific polypeptide comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:24 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:34.

[0597] 71. The idiotype-specific polypeptide of any one of embodiments 53 to 70, wherein the idiotype-specific polypeptide is part of a T cell activating bispecific molecule.

[0598] 72. The idiotype-specific polypeptide of embodiments 53 to 71, wherein the idiotype-specific polypeptide is humanized.

[0599] 73. An isolated polynucleotide encoding the protease-activatable T cell activating bispecific antigen binding molecule of any one of embodiments 1 to 51 or the idiotype-specific polypeptide of any one of embodiments 52 to 72.

[0600] 74. A polypeptide encoded by the isolated polynucleotide of embodiment 73.

[0601] 75 A vector, in particular an expression vector, comprising the polynucleotide according to embodiment 73.

[0602] 76. A host cell comprising the polynucleotide of embodiment 73 or the vector of embodiment 75.

[0603] 77. A method for producing a protease-activatable T cell activating bispecific molecule, the method comprising the following steps: a) culturing the host cell according to Example 76 under conditions suitable for expressing the protease-activatable T cell activating bispecific molecule, and b) recovering the protease-activatable T cell activating bispecific molecule.

[0604] 78. A protease-activatable T cell activating bispecific molecule produced by the method according to Example 77.

[0605] 79. A method for producing an idiotype-specific polypeptide, comprising the steps of: a) culturing the host cell of embodiment 76 under conditions suitable for expression of the idiotype-specific polypeptide, and b) recovering the idiotype-specific polypeptide.

[0606] 80. An idiotype-specific polypeptide produced by the method according to embodiment 79.

[0607] 81. A pharmaceutical composition comprising the protease-activatable T cell activating bispecific molecule according to any one of embodiments 1 to 51 and a pharmaceutically acceptable carrier.

[0608] 82. A pharmaceutical composition comprising the idiotype-specific polypeptide of any one of embodiments 52 to 72 and a pharmaceutically acceptable carrier.

[0609] 83. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 51 or the composition of embodiment 81 or 82 for use as a medicament.

[0610] 84. A protease-activatable T cell activating bispecific molecule for use according to Example 83, wherein the medicament is used to treat cancer or delay its progression, treat immune-related diseases or delay its progression, or enhance or stimulate an immune response or function in an individual.

[0611] 85. The protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 51 or the idiotype-specific polypeptide of any one of embodiments 52 to 72 for use in treating a disease in an individual in need thereof.

[0612] 86. The protease-activatable T cell activating bispecific molecule or idiotype-specific polypeptide of embodiment 85 for use in treating a disease in an individual in need thereof, wherein the disease is cancer.

[0613] 87. Use of the protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 51 or the idiotype-specific polypeptide of any one of embodiments 52 to 72 for the manufacture of a medicament for treating a disease.

[0614] 88. The use according to embodiment 87, wherein the disease is cancer.

[0615] 89. A method of treating a disease in an individual, the method comprising administering to the individual a therapeutically effective amount of a composition comprising the protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 51 or the composition of embodiment 81.

[0616] 90. A method for inducing lysis of a target cell, comprising contacting the target cell with the protease-activatable T cell activating bispecific molecule of any one of embodiments 1 to 51 or the composition of embodiment 81 in the presence of a T cell.

[0617] 91. The method of embodiment 90, wherein the target cell is a cancer cell.

[0618] 92. A method according to embodiment 90 or 91, wherein the target cell expresses a protease capable of activating the protease-activatable T cell activating bispecific molecule.

[0619] 93. A method for reducing the in vivo toxicity of a T cell activating bispecific molecule, comprising connecting an idiotype-specific polypeptide according to any one of embodiments 52 to 72 to a T cell activating bispecific molecule using a protease-cleavable linker to form a protease-activatable T cell activating bispecific molecule, wherein the in vivo toxicity of the protease-activatable T cell activating bispecific molecule is reduced compared to the toxicity of the T cell activating bispecific molecule.

[0620] 116. The invention as hereinbefore described.

[0621] Exemplary sequences

[0622] Table 2: CDR definitions according to Kabat

[0623]

[0624]

[0625]

[0626]

[0627]

[0628]

[0629]

[0630]

[0631]

[0632]

[0633]

[0634]

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641] Examples

[0642] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced given the general description provided above.

[0643] Example 1

[0644] Expression constructs:

[0645] All T cell bispecific molecules are produced in a proprietary 2+1 heterodimer format based on knobs-in-holes technology (two binding moieties for the target antigen and one for CD3). The anti-CD3 binder blocking scFv (stabilized via H44 / L100 disulfide bridges) is fused to the N-terminus of the VH of the CD3 binding Fab in a VHVL order ( Figure 1 ). The linker between scFv and Fab is 33 amino acids long and consists of a protease site embedded in the GS linker sequence.

[0646] The genes of each chain of proTCB were separately inserted into a mammalian expression vector. The expression of all genes was controlled by the human CMV promoter-intron A-5'UTR box. The BGH polyadenylation signal was located downstream of the gene.

[0647] Production of FolR1 proTCB with a protease-cleavable linker

[0648] By transient transfection of Expi293F TM Cells were used to generate bispecific proTCB molecules with different protease linkers. Cells were cultured at 2.5 x 10 6 / ml density inoculated in Expi293 TM Culture medium (Gibco, catalog number 1435101). The expression vector cassette ExpiFectamine (Gibco, ExpiFectamine TM Transfection kit, catalog number 13385544) were mixed in OptiMEM TM10% CO 2 . The cells were then incubated in reduced serum medium (Gibco, catalog number 11520386). After 5 minutes, the two solutions were combined, mixed by pipetting and incubated at room temperature for 25 minutes. The cells were added to the expression vector / ExpiFectamine solution and incubated at 37°C in a shaking incubator with a 5% CO 2 environment for 24 hours. One day after transfection, supplements (Transfection Enhancers 1 and 2, ExpiFectamine TM Transfection kit). After 4 to 5 days, the cell supernatant was harvested by centrifugation and subsequent filtration (0.2 μm filter), and the protein was purified from the harvested supernatant by standard methods as shown below.

[0649] Purification of IgG-like proteins

[0650] Proteins were purified from filtered cell culture supernatants according to standard protocols. Briefly, Fc-containing proteins were purified from filtered cell culture supernatants using protein A affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5; elution buffer: 20 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0, followed by immediate pH neutralization of the sample. The elution was performed by centrifugation (Millipore Proteins were concentrated using ULTRA-15 (Art. Nr.: UFC903096) and aggregated proteins were then separated from monomeric proteins using size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, pH 6.0 (or as otherwise indicated).

[0651] Table 3: Production and purification

[0652]

[0653] Example 2

[0654] Determination of Matriptase cleavage rate using SPR

[0655] The cleavage rate of recombinant Matriptase was studied on a Biacore T200 instrument (Cytiva) using surface plasmon resonance (SPR). Biotinylated CD3ε was immobilized on an S-series Sensorchip SA (Cytiva, 29104992) with a final surface density of 2000–4000 resonance units (RU). FOLR1 proTCB at a concentration of 10 nM was incubated with 50 pM recombinant matriptase (R&D Systems, 3946-SE) at 37°C in PBS-T pH 7.4 and PBS-T pH 6.5. The CD3ε binding response and proTCB activation rate were monitored for up to 10 hours by continuously injecting the proTCB / matriptase mixture onto the surface at a flow rate of 5 μl / min for 30 s. The CD3e surface was regenerated by injecting 10 mM glycine (pH 1.5) at a flow rate of 5 μl / min for 60 s. In the same experiment, a concentration series of 0.16, 0.31, 0.63, 1.25 and 2.5 nM FOLR1 TCB was injected to generate a calibration line and the obtained proTCB binding responses were converted from resonance units (RU) to molar concentrations (nM). The molar concentration of activated proTCB was plotted against the incubation time and the cleavage rate (pM / min) was calculated by determining the slope of each derived line.

[0656] Table 4: Initial cleavage rate at different pH:

[0657]

[0658] Example 3

[0659] Developability of FOLR1proTCBs containing different humanized mask variants

[0660] The selected FOLR1 proTCB molecules with different humanization masks were produced as described in Example 1 and analyzed for stability and developability.

[0661] Table 5: Production and purification

[0662]

[0663] Thermal stability

[0664] Thermal stability was studied by static light scattering (SLS) using the UNcle platform (Unchained Labs). Briefly, 9 μl of a 1 mg / ml proTCB solution was transferred to the sample device of the instrument. A temperature gradient from 30°C to 90°C was applied at a rate of 0.1°C / min. Static light scattering was monitored at a wavelength of 266 nm to determine the aggregation temperature (Tagg).

[0665] Apparent hydrophobicity

[0666] The apparent hydrophobicity was investigated by hydrophobic interaction chromatography (HIC) using high pressure liquid chromatography (HPLC). Briefly, 20 μl of proTCB at a concentration of 1 mg / ml was injected onto a TSKgel ether-5PW column (Tosoh Bioscience 0008641). A linear gradient of 0 to 1.5 M NH4SO4 in 25 mM sodium phosphate was applied over 20 minutes at a column temperature of 40°C at a flow rate of 0.8 ml / min. The detection wavelength was set to 214 nm. Relative retention times were calculated using appropriate reference antibodies.

[0667] FcRn chromatography

[0668] Relative FcRn binding affinity was determined by high pressure liquid chromatography (HPLC). Briefly, 30 μl of proTCB at a concentration of 1 mg / ml was injected onto an FcRn streptavidin sepharose column (Roche Diagnostics 08128057001). According to the manufacturer's recommendations, a step gradient using 20 mM MES sodium salt, 140 mM NaCl pH 5.5 and pH 8.8 was applied at a column temperature of 25°C. The detection wavelength was set to 280 nm. Relative retention times were calculated using appropriate reference antibodies.

[0669] Heparin chromatography

[0670] Relative heparin binding affinity was determined by high pressure liquid chromatography (HPLC). Briefly, 100 μl of proTCB at a concentration of 0.35 mg / ml was injected onto a TSK-Gel Heparin-5PW column (Tosoh Bioscience 13064). A step gradient using 50 mM Tris pH 7.4 and 50 mM Tris, 1 M NaCl, pH 7.4 was applied, respectively. The flow rate was set to 0.8 ml / min and the column temperature was set to 25°C. The detection wavelength was set to 280 nm. Relative retention times were calculated using appropriate reference antibodies.

[0671] Table 6: Results

[0672] parameter P1AF5794 P1AF65795 P1AF5796 <![CDATA[Thermal stability (SLS T agg )]]> 63.5 62.4 62.5 Apparent hydrophobicity (HIC) 0.22 0.21 0.21 FcRn chromatography 0.25 0.25 0.29 Heparin chromatography 0.64 0.64 0.69

[0673] All tested molecules showed good thermal stability (>60°C) and fully acceptable values ​​with regard to hydrophobicity and in FcRn and heparin chromatography.

[0674] Example 4

[0675] Determining the cleavage rates of different proteases using SPR

[0676] The cleavage rates of recombinant proteases (R&D Systems 3946-SEB), proteases-2 (Enzo ALX-201-752), Hepsin (R&D Systems 4776-SE), uPA (Sigma-Aldrich 6273), Legumain (R&D Systems 2199-CY) and furin (R&D Systems 1503-SE) were studied using surface plasmon resonance (SPR) on a Biacore T200 instrument (Cytiva). Biotinylated CD3ε was immobilized on an S-series Sensorchip SA (Cytiva, 29104992) with a final surface density of 2000–4000 resonance units (RU). FOLR1proTCB was incubated in PBS-T pH 7.4 at 37°C with the following concentrations of the different proteases listed above:

[0677] i.10nM proTCB+50pM proteinase

[0678] ii.10nM proTCB+1U proteinase-2

[0679] iii.10nM proTCB+300pM activated Hepsin

[0680] iv.10nM proTCB+5.5nM uPA

[0681] v.10nM proTCB+5nM activated Legumain

[0682] vi.10nM proTCB+3nM furin (1mM CaCl2 added)

[0683] The CD3ε binding response and proTCB activation rate were monitored for up to 10 hours by continuously injecting the proTCB / protease mixture onto the surface at a flow rate of 5 μl / min for 30 seconds. The CD3e surface was regenerated by injecting 10 mM glycine (pH 1.5) at a flow rate of 5 μl / min for 60 s. In the same experiment, a concentration series of 0.16, 0.31, 0.63, 1.25 and 2.5 nM FOLR1TCB was injected to generate a calibration line, and the obtained proTCB binding response was converted from resonance units (RU) to molar concentrations (nM). The molar concentration of activated proTCB was plotted against the incubation time, and the cleavage rate (pM / min) was calculated by determining the slope of each derivative straight line.

[0684] Table 7: Proteinase cleavage rates

[0685]

[0686] Table 8: Proteinase-2 cleavage rates

[0687]

[0688] Table 9: Hepsin cleavage rates

[0689]

[0690] Table 10: uPA cleavage rates

[0691]

[0692] Table 11: Legumain cleavage rates

[0693]

[0694] Table 12: Furin cleavage rates

[0695]

[0696] Example 5

[0697] Developability of FOLR1proTCB (different protease cleavage sites; humanization mask)

[0698] The stability and developability of the selected FOLR1proTCB molecules were analyzed using the same method as in Example 3.

[0699] Table 13: Results

[0700] parameter P1AG0882 P1AG0884 <![CDATA[Thermal stability (SLS T agg )]]> 63.0 62.2 Apparent hydrophobicity (HIC) 0.22 0.22 FcRn chromatography 0.27 0.22 Heparin chromatography 0.65 0.63

[0701] All tested molecules showed good thermal stability (>60°C) and fully acceptable values ​​with regard to hydrophobicity and in FcRn and heparin chromatography.

[0702] Example 6

[0703] Developability of humanized anti-idiotypic IgG

[0704] The binding of anti-idiotypes after incubation for 14 days at 40°C in 20mMHis / HCl, 140mM NaCl pH 6.0 or at 37°C in 1xPBS pH 7.4 was studied by surface plasmon resonance using a Biacore T200 instrument (Cytiva). Briefly, according to the manufacturer's instructions, after injection of the capture reagent, biotinylated anti-human CD3ε antibodies and biotinylated anti-human IgG (Capture Select, Thermoscientific, 7103302500) were fixed on the s series sensor chip CAP (biotin capture kit, Cytiva 28920234). The surface densities obtained were approximately 1000RU and 1500RU, respectively. The anti-idiotype antibodies were injected onto the chip surface at a concentration of 1μg / ml for 30 seconds at a flow rate of 5μl / min. Dissociation was monitored for 30 seconds. After each injection, the chip surface was regenerated by injecting 2M guanidine hydrochloride, 0.5M NaOH for 120 seconds. Bulk refractive index differences were corrected by subtracting the response obtained from the simulated surface.

[0705] To normalize the binding signal of the anti-idiotypic antibody, the binding response of the anti-human CD3ε antibody surface was divided by the binding response of the anti-human IgG surface. The relative activity concentration was obtained by dividing the normalized response of the stressed sample by the normalized response of the unstressed reference sample of each molecule.

[0706] Table 14: Results

[0707]

[0708] Example 7

[0709] Developability of proTCB

[0710] The binding of proTCB after incubation for 14 days in 20mMHis / HCl, 140mM NaCl pH 6.0 at 40°C or in 1xPBS pH 7.4 at 37°C was studied by surface plasmon resonance using a Biacore T200 instrument (Cytiva). Briefly, mouse anti-huIgG CH2 PG-LALA antibody (P1AE2335) and human CD3ε (P1AA6119) were immobilized on an S-series sensor chip CM5 (Cytiva) using standard amine coupling chemistry. The obtained ligand densities were approximately 8500RU and 7000RU, respectively. For FolR1 binding assessment, proTCB was captured onto the anti-human IgGPG-LALA surface at a concentration of 2μg / ml and a flow rate of 10μl / min for 75 seconds. Subsequently, human FolR1 (P1AD6798) was injected at a concentration of 900nM at a flow rate of 10μl / min for 120 seconds. Dissociation was monitored for 120 seconds. After each injection of human FolR1, the surface was regenerated by injecting 20mM NaOH for 35 seconds. For CD3ε binding assessment, proTCB was injected onto the CD3ε surface at a concentration of 10μg / ml at a flow rate of 10μg / ml for 90 seconds. Dissociation was monitored for 90 seconds. After each injection, the surface was regenerated by injecting 10mM glycine pH 2.1 for 70 seconds. The bulk refractive index difference was corrected for each interaction by subtracting the response obtained from the simulated surface.

[0711] To normalize the binding signal of proTCB, the FolR1 and CD3ε binding responses were divided by the binding response of the anti-human IgG PG-LALA surface. The relative activity concentration was obtained by dividing the normalized response of the stressed sample by the normalized response of the unstressed reference sample (FolR1) or the unmasked control molecule (CD3ε) of each molecule.

[0712] Table 15: Relative FolR1 binding

[0713]

[0714] Table 16: Relative CD3 binding

[0715]

[0716] Example 8

[0717] In vivo stability and pharmacokinetic characteristics of different linkers after a single injection in NSG mice

[0718] A single dose of 5 mg / kg pro-FolR1-TCB molecules containing selective cleavage sites for different proteases was injected into NSG mice. Figure 2As shown in , all mice were injected iv with 200 μl of the appropriate solution. In order to obtain the appropriate amount of compound per 200 μl, the stock solution was diluted with histidine buffer (Table 17). At 24 hours, the 7th day and the 10th day, two mice in each group were bled at each time point. The injection compound in the serum samples was analyzed by ELISA.

[0719] Molecular detection was performed by LBA (ligand binding assay) as follows. Serum samples from mice treated with P1AF5419 (cleavage site: HQARK), P1AF5420 (cleavage site: PQARK) or P1AE6554 (typical FolR1 2+1TCB) were analyzed using an ECLIA method with specificity for human CH1 / PGLALA domain containing proteins ("total assay") and an ECLIA method with capture using CD3 anti-ID antibody and detection using anti-PGLALA specific antibody using a cobas e411 instrument ("activity assay").

[0720] For the "total assay", test samples of P1AF5419 (cleavage site: HQARK) (004-09), P1AF5420 (cleavage site: PQARK) (004-06), or P1AE6554 (typical FolR1 2+1 TCB), primary detection antibody mAb <h-igg>11-1.19.31-IgG-Bi, second detection antibody mAb<H-Fc(PGLALA)> M-1.7.24-IgG-Ru and SA beads were added stepwise to the detection vessel and incubated for 9 minutes in each step.

[0721] For the "activity assay", the test sample of FolR1 TCB (007-19), the primary detection antibody mAb <ch2527>rH-4.24.72-IgG()-Bi, second detection antibody mAb<H-Fc(PGLALA)> M-1.7.24-IgG-Ru and SA beads were added stepwise to the detection container and incubated for 9 minutes in each step. Finally, the complex bound by the SA beads was detected by a measuring unit, which repeatedly numbered the counts of the SA beads. The counts were proportional to the analyte concentration in the test sample.

[0722] Table 17: Preparation of stock solutions

[0723]

[0724] Serum analysis of mice dosed with 5 mg / kg of FOLR1-TCB or FOLR1 pro-TCB showed low levels of active TCB, less than 5% of total pro-TCB, at all time points measured for both FOLR1pro-TCB molecules containing either the HQARK or PQARK cleavage site. For canonical (non-masked) FOLR1-TCB, 100% of active TCB was detected ( Figure 3 ).

[0725] Example 9

[0726] Efficacy study using pro-FOLR1-TCB constructs containing selective cleavage sites for different proteases in BC004 PDXs of humanized mice

[0727] Human breast cancer patient-derived xenografts HER2+ER- xenograft model BC004 were purchased from OncoTest (Freiburg, Germany). Tumor fragments were digested with collagenase D and DNase I (Roche), counted, and injected at 1×10 6 BC004 cells were added to a total volume of 100 μl of a mixture of RPMI and Matrigel, which was then injected subcutaneously into the flank of anesthetized mice using a 22G to 30G needle.

[0728] Female NSG mice (Jackson Laboratories), 4-5 weeks old at the start of the experiment, were maintained under specific pathogen-free conditions with a 12 h light / 12 h dark daily cycle according to regulatory guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by the local authorities (P 2011 / 128). After arrival, the animals were maintained for one week to acclimate to the new environment and observed. Continuous health status monitoring was performed regularly.

[0729] Female NSG mice were injected ip with 15 mg / kg of busulfan, followed by iv injection of 1x10 isolated from umbilical cord blood one day later. 5 Individual hematopoietic stem cells. At 14-16 weeks after stem cell injection, mice were bled sublingually and blood was analyzed by flow cytometry for successful humanization. Effectively transplanted mice were randomized into different treatment groups according to their human T cell frequencies. At this time, mice were injected with tumor PDX cells, and when the tumor size reached about 200mm3 (the 28th day), they were treated once a week with compound or histidine buffer (solvent). All mice were injected with 200 μl of appropriate solution iv. In order to obtain an appropriate amount of compound per 200 μl, the stock solution was diluted with histidine buffer when necessary (Table 18).

[0730] Tumor growth was measured twice weekly using calipers ( Figure 2 ), and the tumor volume was calculated as follows:

[0731] T v :(W 2 / 2) x L (W: width, L: length)

[0732] At termination (day 58), mice were sacrificed and tumors and spleens were removed and weighed.

[0733] Figure 5A Tumor growth kinetics (mean, + / - SEM) in the most effective treatment group as well as individual tumor growth for each mouse are shown. As described herein, FOLR1 pro-TCB containing the PQARK cleavage site was determined to be the best pro-TCB tested in this study. In addition, no efficacy was seen in the group treated with FOLR1 pro-TCB containing a non-cleavable linker. FIG. 5A to FIG. 5G In , tumor weights at termination are depicted for all treatment groups. This readout clearly supports the findings in tumor growth kinetics and shows that pro-TCBs containing the PQARK cleavage site result in comparable tumor weights at termination compared to canonical FolR1 TCBs.

[0734] Table 18: Preparation of stock solutions

[0735]

[0736] Example 10

[0737] Production and purification of FOLR1proTCB using clone 22 as a CD3 binder

[0738] P1AI3541 (FOLR1proTCB with a PQARK cleavable linker, SEQ ID Nos: 45, 46, 56), P1AI3542 (FOLR1proTCB with a non-cleavable linker, SEQ ID Nos: 45, 46, 59) and P1AI3543 (unmasked TCB, SEQ ID NOs: 45, 57, 58) were transiently produced in HEK293 cells. Purification was performed using protein A affinity chromatography followed by size exclusion chromatography according to standard procedures.

[0739] Table 19: Production output and quality

[0740]

[0741] Example 11

[0742] Jurka NFAT activation induced by protease-activatable FOLR1 TCB containing CD3 binder clone 22

[0743] Jurkat NFAT activation mediated by FOLR1TCB (SEQ ID NOs: 45, 57, 58) or FOLR1 pro-TCB (SEQ ID Nos: 45, 46, 56) was measured after incubation with TCB for cross-linking and huFOLR1-coated beads ( Figure 6 ). FOLR1 TCB was used as a positive control because it does not contain a mask that blocks CD3 binding. FOLR1 pro-TCB containing a CD3 mask with a non-cleavable G4S linker was used as a negative control. The cleavable FOLR1 pro-TCB containing a PQARK cleavage site was incubated overnight at room temperature with human rec protease to cleave off the CD3 mask. Jurkat NFAT activation was measured by luminescence reading using a Tecan Spark Reader with an acquisition time of 0.5 seconds after incubation at 37°C in a humidified incubator for 24 hours. Each point represents the average of three replicates. Standard deviations are indicated by error bars (n=1).

Claims

1. A protease-activatable T cell-activating bispecific molecule comprising (a) a first antigen binding portion capable of binding to CD3; (b) a second antigen binding moiety capable of binding to a target cell antigen; and (c) a masking moiety covalently linked to the T cell activating bispecific molecule via a peptide linker, wherein the masking moiety is capable of binding to the idiotype of the first antigen binding moiety or the second antigen binding moiety, thereby reversibly concealing the first antigen binding moiety or the second antigen binding moiety, The linker comprises a protease recognition sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

2. The protease-activatable T cell activating bispecific molecule of claim 1, wherein the masking moiety is covalently attached to the first antigen binding moiety and reversibly conceals the first antigen binding moiety.

3. The protease-activatable T cell activating bispecific molecule of claim 1 or 2, wherein the masking moiety is covalently linked to the heavy chain variable region of the first antigen binding moiety.

4. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 3, wherein the masking moiety is a scFv.

5. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 4, wherein (i) the second antigen binding portion is a conventional Fab, or (ii) the second antigen binding portion is a crossover Fab molecule in which the variable regions or constant regions of the Fab light chain and the Fab heavy chain are exchanged.

6. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 5, wherein the first antigen binding moiety is a conventional Fab molecule. 7 . The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 6 , comprising a third antigen binding portion which is a Fab molecule capable of binding to a target cell antigen.

8. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 7, wherein the third antigen binding moiety is identical to the second antigen binding moiety. 9 . The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 8 , wherein the target cell antigen is FolR1.

10. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 9, wherein the first antigen binding moiety and the second antigen binding moiety are fused to each other, optionally via a peptide linker.

11. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 10, wherein the second antigen binding moiety is fused to the N-terminus of the Fab heavy chain of the first antigen binding moiety at the C-terminus of the Fab heavy chain. 12 . The protease-activatable T cell activating bispecific molecule according to claim 1 , further comprising an Fc domain composed of a first subunit and a second subunit capable of stably associating. 13 . The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 12, wherein the Fc domain is an IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain.

14. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 13, wherein the Fc domain exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain.

15. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 14, wherein the antigen binding portion capable of binding to CD3 comprises: a heavy chain variable (VH) region (a) heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SYAMN (SEQ ID NO: 1); (b) HCDR2 amino acid sequence of RIRSKYNNYATYYADSVKG (SEQ ID NO: 2); (c) the HCDR3 amino acid sequence of ASNFPASYVSYFAY (SEQ ID NO: 3); and a light chain variable (VL) region comprising: (d) the light chain complementarity determining region (LCDR) 1 amino acid sequence of GSSTGAVTTSNYAN (SEQ ID NO: 7); (e) LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and (f) a LCDR3 amino acid sequence selected from ALWYSNLWV (SEQ ID NO: 9).

16. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 15, wherein the antigen binding portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 5; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

10.

17. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 14, wherein the antigen binding portion capable of binding to CD3 comprises: a heavy chain variable (VH) region comprising (a) heavy chain complementarity determining region (HCDR) 1 amino acid sequence of SYAMN (SEQ ID NO: 1); (b) HCDR2 amino acid sequence of RIRSKYNNYATYYADSVKG (SEQ ID NO: 2); (c) HCDR3 amino acid sequence of HTTFPSSYVSYYGY (SEQ ID NO: 4); and a light chain variable (VL) region comprising: (d) the light chain complementarity determining region (LCDR) 1 amino acid sequence of GSSTGAVTTSNYAN (SEQ ID NO: 7); (e) LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and (f) a LCDR3 amino acid sequence selected from ALWYSNLWV (SEQ ID NO: 9).

18. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 15, wherein the antigen binding portion capable of binding to CD3 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 6; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

10.

19. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 18, wherein the masking moiety comprises: a VH region comprising: (a) the HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15), (b) a HCDR2 amino acid sequence selected from the group consisting of WINTETGEPRYTDDFKG (SEQ ID NO: 16), WINTETGEPRYTDDFTG (SEQ ID NO: 17) and WINTETGEPRYTQGFKG (SEQ ID NO: 18); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25) or KSSKSVSTSSYSYMH (SEQ ID NO: 26); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28) or QQSREFPYT (SEQ ID NO: 29).

20. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 19, wherein the masking moiety comprises: a VH region comprising: (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15); (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

21. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 19, wherein the masking moiety comprises: a VH region comprising: (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15); (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFKG (SEQ ID NO: 16); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

22. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 19, wherein the masking moiety comprises: a VH region comprising: (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15); (b) HCDR2 amino acid sequence of WINTETGEPRYTDDFTG (SEQ ID NO: 17); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

23. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 19, wherein the masking moiety comprises: a VH region comprising: (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15); (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of KSSKSVSTSSYSYMH (SEQ ID NO: 26); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QHSREFPYT (SEQ ID NO: 28).

24. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 19, wherein the masking moiety comprises: a VH region comprising: (a) HCDR1 amino acid sequence of DYSMN (SEQ ID NO: 15); (b) HCDR2 amino acid sequence of WINTETGEPRYTQGFKG (SEQ ID NO: 18); (c) HCDR3 amino acid sequence of EGDYDVFDY (SEQ ID NO: 19); and a VL region comprising: (d) LCDR1 amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO: 25); (e) the LCDR2 amino acid sequence of YVSYLES (SEQ ID NO: 27); and (f) LCDR3 amino acid sequence of QQSREFPYT (SEQ ID NO: 29).

25. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 24, wherein the second antigen binding portion is capable of binding to FolR1 and comprises: a VH region comprising: a) HCDR1 amino acid sequence of NAWMS (SEQ ID NO: 11); b) the HCDR2 amino acid sequence of RIKSKTDGGTTDYAAPVKG (SEQ ID NO: 12); and c) HCDR3 amino acid sequence of PWEWSWYDY (SEQ ID NO: 13); and a VL region comprising: d) LCDR1 of GSSTGAVTTSNYAN (SEQ ID NO:7); e) the LCDR2 amino acid sequence of GTNCRAP (SEQ ID NO: 8); and f) LCDR3 amino acid sequence of ALWYSNLWV (SEQ ID NO: 9).

26. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 25, wherein the antigen binding portion capable of binding to FolR1 comprises: a VH region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 14; and / or a VL region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

10.

27. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 26, wherein the protease-cleavable linker comprises the protease recognition sequence PQARK (SEQ ID NO: 41).

28. An idiotype-specific polypeptide for reversibly concealing an anti-CD3 antigen binding site of a molecule, wherein the idiotype-specific polypeptide is covalently linked to the molecule via a peptide linker, wherein the linker comprises a protease recognition sequence XQARK (SEQ ID NO: 39), wherein X is histidine (H) or proline (P).

29. The idiotype-specific polypeptide of claim 28, wherein the idiotype-specific polypeptide is an anti-idiotype scFv.

30. The idiotype-specific polypeptide of claim 29, wherein the molecule is a T cell activating bispecific molecule.

31. The idiotype-specific polypeptide of claim 30, wherein the linker comprises a protease recognition sequence PQARK (SEQ ID NO: 41).

32. A pharmaceutical composition comprising the protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27 and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising the idiotype-specific polypeptide according to any one of claims 28 to 31 and a pharmaceutically acceptable carrier.

34. An isolated polynucleotide encoding the protease-activatable T cell activating bispecific antigen binding molecule according to any one of claims 1 to 27.

35. An isolated polynucleotide encoding the idiotype-specific polypeptide of any one of claims 28 to 31.

36. A vector, in particular an expression vector, comprising the polynucleotide according to claim 34 or 35.

37. A host cell comprising the vector according to claim 36.

38. A method for producing a protease-activatable T cell-activating bispecific molecule, the method comprising: The following steps are involved: a) culturing the host cell according to claim 37 under conditions suitable for expressing the protease-activatable T cell activating bispecific molecule, and b) recovering the protease-activatable T cell activating bispecific molecule.

39. The protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27 for use as a medicament.

40. The protease-activatable T cell activating bispecific molecule for use according to claim 39, wherein the medicament is for treating cancer or delaying its progression, treating an immune-related disease or delaying its progression, or enhancing or stimulating an immune response or function in an individual.

41. Use of the protease-activatable T cell activating bispecific molecule according to any one of claims 1 to 27 for the manufacture of a medicament for treating a disease.

42. Use of the protease-activatable T cell activating bispecific molecule according to claim 41, wherein the disease is cancer.

43. A method of treating a disease in an individual, the method comprising administering to the individual a therapeutically effective amount of a composition comprising the protease-activatable T cell activating bispecific molecule of any one of claims 1 to 27.

44. The method of claim 43, for treating or delaying progression of cancer.